IND [ZIP_CODE]  AGS -v PLUS  
Protocol, v 4.0 01 May  2020  AGS -v PLUS Mosquito Vax  
 
  
OCRPRO/DCR/NIAID/NIH  
CONFIDENTIAL   Page 1 of 67  
 
 
 
Randomized, Double -Blind, Placebo -Controlled, Phase 1  
Study in Healthy Volunteers to Evaluate the Safety and  
Immunogenicity of AGS -v PLUS , a Universal Mosquito -Borne  
Disease Vaccine   
  
 
 
  
Sponsored by  
[CONTACT_916] (OCRPRO)  
Division of Clinical Research ( DCR ) 
National Institute of Allergy and Infectious Diseases  
National Institutes of Health  
  
Protocol #:  HP-00084004  
IND # [ZIP_CODE]   
  
Vaccine Manufactured by   
[CONTACT_40676] I nvestigator  
Matthew B. Laurens , MD, MPH  
 
Co-Investigator  
Matthew J. Memoli, MD, MS   
Version Number and Date  
Version 4.0  
01 May 2020 
IND [ZIP_CODE]  AGS -v PLUS  
Protocol, v 4.0 01 May  2020  AGS -v PLUS Mosquito Vax  
 
  
OCRPRO/DCR/NIAID/NIH  
CONFIDENTIAL   Page 2 of 67 TEAM ROSTER  
Principal Investigator:  
 
 
 
 
 
 
 
 
 
[CONTACT_15957]-Investigator  Matthew B. Laurens , MD, MPH  
Associate [CONTACT_40757] for Vaccine Development and Global Health  
(CVD)  
University of Maryland School of Medicine   
[ADDRESS_42324], Room 480  
Baltimor e, MD 2 1201  
Tel: [PHONE_712]   
Email: mlaurens @som.umaryland.edu   
 
 
Matthew J. Memoli, MD, MS  
Direc tor, LID Clinical Studies Unit  
Viral Pathogenesis and Evolution Section  
Laboratory of Infectious Diseases  
National Institute of Allergy and Infectious Diseases  
National Institutes of Health  
MSC [ADDRESS_42325]  
Bethesda, MD [ZIP_CODE] -3203  
UNITED STATES  
Email:  [EMAIL_781]  
Phone: 301 -443-5971  
 
Associate Investigators:  DeAnna Friedman -Klabanoff, MD  
University of Maryland School of Medicine  
Tel 410 -706-5328  
Email: dfriedma [EMAIL_782]  
 
Mark A. Travassos, MD, MS   
Assistant [CONTACT_40758] of Maryland School of Medicine   
Tel: [PHONE_713]   
Email: mtravass @som.umaryland.edu   
  
Andrea A. Berry, MD  
Assistant [CONTACT_40758] of Maryland School of Medicine  
Tel: 410 -706-5328  
Email: [EMAIL_783]  
 
Kirsten E. Lyke, MD  
[CONTACT_40758] of Maryland School of Medicine  
Tel: 410 -706-5328  
Email: [EMAIL_784]  
 
Miriam K. Laufer, MD, MPH  
Professor  
IND [ZIP_CODE]  AGS -v PLUS  
Protocol, v 4.0 01 May  2020  AGS -v PLUS Mosquito Vax  
 
  
OCRPRO/DCR/NIAID/NIH  
CONFIDENTIAL   Page 3 of 67 University of Maryland School of Medicine  
Tel: 410 -706-5328  
Email: [EMAIL_785]  
 
Amed Ouattara, PhD  
Research Associate  
University of Maryland School of Medicine  
Tel: 410 -706-5328  
Email: [EMAIL_786]  
 
IRB Contact:  [CONTACT_40677]: 410 -706-5037  
Fax: [PHONE_714]  
Email: [EMAIL_787]  
 
Sponsor Medical Monitor:  H. Preston Holley, MD, FACP, FIDSA [C]  
Sponsor Medical Monitor  
Clinical Monitoring Research Program Directorate 
(CMRPD)  
Frederick National Laboratory for Cancer Research  
Leidos Biomedical Research  
Tel: [PHONE_715]  
Email: [EMAIL_788]  
 
Study Statistician:  Sally Hunsberger, PhD  
Mathematical Statistician   
Biostatistics Research Branch   
National Institute of Allergy and Infectious  
Diseases / NIH / U.S. DHHS  
Tel: [PHONE_716]  
Email: [EMAIL_789]   
 
Study Staff CVD : Lisa Chrisley, RN  
Tel: 410 -706-6156  
Email: [EMAIL_790]  
 
Faith Pa’ahana -Brown, RN  
Tel: 410 -706-6156  
Email: [EMAIL_791]  
 
Collaborators:  Jesus G. Valenzuela, PhD  
LMVR, VMBS, NIAID  
Tel: 301 -761-5070  
Email: [EMAIL_792]  
 
Olga Pleguezuelos , PhD  
PepTcell Ltd (t/a SEEK)  
IND [ZIP_CODE]  AGS -v PLUS  
Protocol, v 4.0 01 May  2020  AGS -v PLUS Mosquito Vax  
 
  
OCRPRO/DCR/NIAID/NIH  
CONFIDENTIAL   Page [ADDRESS_42326]  
London, EC2Y 8AD, [LOCATION_008]  
Tel: [PHONE_717]   
Email: [EMAIL_793]  
 
 
IND [ZIP_CODE]  AGS -v PLUS  
Protocol, v 4.0 01 May  2020  AGS -v PLUS Mosquito Vax  
 
  
OCRPRO/DCR/NIAID/NIH  
CONFIDENTIAL   Page [ADDRESS_42327] OF ABBREVIA TIONS  ................................ ................................ ................................ ........................  9 
PROTOCOL SUMMARY  ................................ ................................ ................................ ..........................  11 
PRÉCIS  ................................ ................................ ................................ ................................ ......................  14 
1  Background Information and Scientific Rationale ................................ ................................ ...........  15 
2  Study Objectives  ................................ ................................ ................................ ...............................  25 
2.1  Primary Objective  ................................ ................................ ................................ ......................  25 
2.2  Secondary Objectives  ................................ ................................ ................................ ...............  25 
2.3  Exploratory Objectives  ................................ ................................ ................................ ..............  25 
3  Study Design  ................................ ................................ ................................ ................................ ..... 26 
3.1  Description of the Study Design  ................................ ................................ ...............................  26 
3.2  Study Endpoints  ................................ ................................ ................................ .........................  27 
4  Study Enrollment  ................................ ................................ ................................ ...............................  27 
4.1 Inclusion Criteria  ................................ ................................ ................................ ........................  28 
4.4  Exclusion Criteria  ................................ ................................ ................................ .......................  28 
4.5  Justification for Exclusion of Pregnant Women and Children (Special Populations)  ...........  30 
4.6 Reasons for Withdrawal  ................................ ................................ ................................ ............  30 
4.7 Handling of Withdrawals  ................................ ................................ ................................ ...........  30 
4.8 Termination of Study  ................................ ................................ ................................ .................  31 
5  Study  Agents/Interventions  ................................ ................................ ................................ ..............  31 
5.1 Description ................................ ................................ ................................ ................................ ....... 31 
5.1.1 AGS -v PLUS ................................ ................................ ................................ .............................  31 
5.1.2 Adjuvants  ................................ ................................ ................................ ................................ .. 31 
5.1.3 Placebo  ................................ ................................ ................................ ................................ ..... 32 
5.2 Study Agents Storage and Stability ................................ ................................ ...............................  32 
5.3  Preparation  ................................ ................................ ................................ ................................ . 32 
5.4  Dosing and Administration  ................................ ................................ ................................ ........  32 
5.5 Modification of Study Intervention/Investigational Product for a Participant .........................  [ADDRESS_42328] Accountability  ................................ ................................ ................................ .............  33 
5.6.2 Accountability of Study Supplies  ................................ ................................ ............................  34 
5.6.3 Retention of Samples  ................................ ................................ ................................ ..............  34 
5.7  Concomitant Medications and Procedures ................................ ................................ ..............  34 
6  Study Schedule  ................................ ................................ ................................ ................................ . 34 
6.1 Screening (Days -60 to 0) (outpatient visit)  ................................ ................................ .............  35 
6.2  Enrollment/Baseline and First Vaccination (Day 1) (outpatient visit)  ................................ .... 36 
6.3 Day 8 (+2 days) (phone call) ................................ ................................ ................................ ..... 36 
6.4 Day 22 (+/ - 3 days) (outpatient visit)  ................................ ................................ ........................  36 
6.5 Day 29 (+2 days) (phone call)  ................................ ................................ ................................ .. 37 
6.6  Day 43 Mosquito Feeding (+7 days) (outpatient visit)  ................................ ............................  37 
6.7  Day 45 (+/ - 1 day) (outpatient visit)  ................................ ................................ ..........................  38 
6.8  Mosquito Feeding follow -up (Day 50 + 2 days) ................................ ................................ ....... 38 
6.9  Telephone Safety Follow -up (Day 181 +14 days, and Day 366 +14 days)  ..........................  39 
IND [ZIP_CODE]  AGS -v PLUS  
Protocol, v 4.0 01 May  2020  AGS -v PLUS Mosquito Vax  
 
  
OCRPRO/DCR/NIAID/NIH  
CONFIDENTIAL   Page 6 of 67 7  Study Procedures/ Evaluations  ................................ ................................ ................................ ........  40 
7.1  Clinical and Laboratory Evaluations  ................................ ................................ .........................  40 
7.1.1 Laboratory Testing of Collected Samples for Primary and Secondary Endpoints  .............  40 
7.2  Reactogenicity ................................ ................................ ................................ ............................  41 
7.3 Mosquito Bite Assessment ................................ ................................ ................................ ........  41 
8  Potential Risks and Benefits ................................ ................................ ................................ .............  41 
8.1  Risks of Placebo administration  ................................ ................................ ...............................  41 
8.2  Risks of AGS -v PLUS ± adjuvant vaccination  ................................ ................................ .........  41 
8.3  Risks of adjuvant ................................ ................................ ................................ ........................  43 
8.4  Risks of blood draw  ................................ ................................ ................................ ...................  44 
8.5  Risks of Aedes aegypti and Aedes albopi[INVESTIGATOR_40611]  ................................ .........  44 
8.6 Risk of Skin Biopsies  ................................ ................................ ................................ .................  44 
8.6  Potential Benefits  ................................ ................................ ................................ .......................  45 
9  Research Use of Stored Human Samples, Specimens, or Data  ................................ ..................  45 
10  Data Sharing Plan  ................................ ................................ ................................ .............................  46 
10.1  Sharing of Human Data  ................................ ................................ ................................ .........  46 
11  Remuneration Plan  ................................ ................................ ................................ ...........................  46 
12  Assessment of Safety  ................................ ................................ ................................ .......................  46 
12.1  Documenting, Recording, and Reporting AEs ................................ ................................ ..... 46 
12.2  Definitions  ................................ ................................ ................................ ...............................  47 
12.3  Investigator Assessment of AEs  ................................ ................................ ...........................  49 
12.3.1 Severity  ................................ ................................ ................................ ................................ ... 49 
12.3.2 Causality  ................................ ................................ ................................ ................................ . 50 
12.4  Investigator Reporting Responsibilities to the Sponsor  ................................ ......................  50 
12.4.1 AEs ................................ ................................ ................................ ................................ ..........  50 
12.4.2 SAEs  ................................ ................................ ................................ ................................ ....... 51 
12.4.3 Unanticipated Problems  ................................ ................................ ................................ ........  51 
12.4.4 Pregnancy  ................................ ................................ ................................ ..............................  51 
12.5  Investigator Reporting Responsibilities to the University of Maryland, Baltimore (UMB) 
IRB  ................................ ................................ ................................ ................................ .................  51 
12.5.1 Reporting Protocol Deviations  ................................ ................................ ..............................  51 
12.5.2 Special Reporting Situations ................................ ................................ ................................ . 52 
12.5.3 Expedited Reporting to the UMB IRB ................................ ................................ ...................  52 
12.5.4 Waiver of Reporting Anticipated Protocol Deviations, Expected UPnonAEs and Deaths 
to the UMB IRB ................................ ................................ ................................ ................................ .. 52 
12.5.5 Annual Reporting to the UMB IRB ................................ ................................ ........................  52 
12.6  Follow -Up of AEs and SAEs  ................................ ................................ ................................ . 52 
12.7  Sponsor’s Reporting Responsibilities ................................ ................................ ...................  53 
12.8  Pausing Rules for an Individual Participant  ................................ ................................ .........  53 
12.8.1 Reporting a Pause  ................................ ................................ ................................ .................  53 
12.8.2 Resumption of a Paused Study  ................................ ................................ ............................  53 
12.9  Halting Rules for the Protocol  ................................ ................................ ...............................  54 
12.9.1 Reporting a Study Halt  ................................ ................................ ................................ ..........  54 
12.9.2 Resumption of a Halted Study  ................................ ................................ ..............................  54 
12.10 Study Discontinuation ................................ ................................ ................................ .................  54 
12.11 Premature Withdrawal of a Participant  ................................ ................................ .....................  55 
12.12 Replacement of a Participant  ................................ ................................ ................................ .... 55 
12.13 Safety Oversight  ................................ ................................ ................................ .........................  55 
IND [ZIP_CODE]  AGS -v PLUS  
Protocol, v 4.0 01 May  2020  AGS -v PLUS Mosquito Vax  
 
  
OCRPRO/DCR/NIAID/NIH  
CONFIDENTIAL   Page 7 of 67 12.13.1 Safety Review and Communications Plan (SRCP)  ................................ ..........................  [ADDRESS_42329]  ................................ ................................ .....................  56 
13  Site Monitoring Plan  ................................ ................................ ................................ ..........................  56 
14  Statistical Considerations  ................................ ................................ ................................ .................  57 
14.1  Study Hypothesis  ................................ ................................ ................................ ...................  57 
14.2  Sample Size Justification and Analysis Plan  ................................ ................................ ....... 57 
14.3  Analysis Plan  ................................ ................................ ................................ ..........................  59 
14.3.1 Interim  Analysis  ................................ ................................ ................................ .......................  60 
15  Ethics/Protection of Human Participants  ................................ ................................ .........................  [ADDRESS_42330] Retention  ................................ ................................ ................................ ...................  61 
SCIENTIFIC  REFERENCES ................................ ................................ ................................ ....................  62 
Appendix A: Schedule of Procedures/Evaluations  ................................ ................................ .................  64 
Appendix B: Blood Volumes for Specimen Collection  ................................ ................................ ...........  65 
Appendix C: Toxicity Tables  ................................ ................................ ................................ .....................  66 
Appendix D: UMB IRB reporting guidelines  ................................ ................................ ............................  67 
 
 
IND [ZIP_CODE]  AGS -v PLUS  
Protocol, v 4.0 01 May  2020  AGS -v PLUS Mosquito Vax  
 
  
OCRPRO/DCR/NIAID/NIH  
CONFIDENTIAL   Page [ADDRESS_42331] 2 SAE’s for samples sizes of [ADDRESS_42332] of immunization with salivary g land protein fractions on mosquito fecundity. ...........  18 
Figure 3. IFN  response in mice with AGS -mix (AGS -v) or vehicle  ................................ ......................  19 
Figure 4. Total Ig and IgG2a AGS -mix (AGS -v)-specific antibody responses in mice measured by 
[CONTACT_6428].  ................................ ................................ ................................ ................................ ........................  [ADDRESS_42333] -vaccination with two doses of a Non Relevant Peptide (NRP) mix or AGS -v 15 days 
apart.  ................................ ................................ ................................ ................................ ..........................  21 
Figure 6. IFN - secretion by [CONTACT_40678] -v PLUS formulated in 
different adjuvants (Montanide ISA -51, Alhydrogel® and Adju -phos).  ................................ ..................  [ADDRESS_42334] AGS -v PLUS or the single peptides in the serum (1:400) of 
mice vaccinated with Placebo or AGS -v PLUS formulated in Montanide ISA -51, Alhydrogel® or 
Adju-phos adjuvants at pre -vaccination (day 0) and  post-vaccination (day 42). Y axis=corrected 
absorbance, X -axis= vaccination received.  ................................ ................................ ............................  [ADDRESS_42335] AGS -v of mice vaccinated with Placebo or AGS -v PLUS 
formulated in Montanide ISA -51, Alhydrogel® or Adju -phos adjuvants at pre -vaccination (day 0), [ADDRESS_42336] dose (day 21) and 21 days after the second dose (day 42). Y axis=corrected 
absorbance, X -axis= vaccination received.  ................................ ................................ ............................  [ADDRESS_42337] OF APPENDICES  
 
Appendix A: Schedule of Procedures/Evaluations  ................................ ................................ .................  64 
Appendix B: Blood Volumes fo r Specimen Collection  ................................ ................................ ...........  65 
Appendix C: Toxicity Tables  ................................ ................................ ................................ .....................  66 
Appendix D: UMB IRB reporting guidelines  ................................ ................................ ............................  67 
 
 
 IND# [ZIP_CODE]  AGS -v PLUS  
Protocol, v 4.0 01 May  2020 AGS -v PLUS Mosquito Vax   
 
  
OCRPRO/DCR/NIAID/NIH  
CONFIDENTIAL  Page [ADDRESS_42338]    artemisinin -based combination therapy   
AE    adverse event  
AR    adverse reaction  
BMI  
BTRIS    body mass index  
Biomedical Translational Research Information System   
CFR    Code of Federal Regulations  
CRF  case report form  
CSO   Clinical Safety Office  
CSU 
CVD    Clinical Studies Unit  
Center for Vaccine Development and Global Health  (University of Maryland School 
of Medicine)  
DCR   Division of Clinical Research  
DSMB  Data and Safety Monitoring Board  
ECG   electrocardiogram  
ELISA   enzyme -linked immunosorbent assay  
EP European Pharmacopeia  
FACS  fluorescence -activated cell sorting  
FDA    U.S. Food and Drug Administration  
FLU-v influenza vaccine  
FMOC  9-fluorenylmethoxycarbonyl  
GCP   Good Clinical Practice  
HIV    human immunodeficiency virus  
HIV-v human immunodeficiency virus vaccine  
HLA human leukocyte antigen  
HRPP   Human Research Protection Program  
ICH    International Council  for Harmonisation  of Technical Requirements for 
Pharmaceuticals for Human Use  
IFA    Incomplete Freund’s adjuvant  
IFN- interferon gamma  
IgE    immunoglobulin E 
IgG immunoglobulin G  
IgM immunoglobulin M  
IND    Investigational New Drug  application   
IP    investigational product  
IRB    institutional review board  
IV    intravenous  
kDa kilodalton  
LID    Laboratory of Infectious Disease s  
MHC  
MTT  major histocompatibility complex  
Dimethylthiazol  
NIAID   National Institute of Allergy and Infectious Diseases   
NIH    National Institutes of Health  
OCRPRO  Office of Clinical Research Policy and Regulatory Operations  
OHRP   Office for Human Research Protections  
PBMC   peripheral blood mononuclear cell  
PI    [INVESTIGATOR_40612]# [ZIP_CODE]  AGS -v PLUS  
Protocol, v 4.0 01 May  2020 AGS -v PLUS Mosquito Vax   
 
  
OCRPRO/DCR/NIAID/NIH  
CONFIDENTIAL  Page 10 of 67 S[LOCATION_003]R  
TEAE  serious  and unexpected  suspected adverse reaction  
Treatment Emergent Adverse Event   
Th1    Type 1 T helper cells  
Th2 Type 2 T helper cells  
UMB  University of Maryland , Baltimore  
UP    Unanticipated Problem  
UPnonAE  Unexpected Problem that is not an AE  
USP    [LOCATION_002] Pharmacopeia  
WBC  white blood cells  
WFI    water for injection  
 IND# [ZIP_CODE]  AGS -v PLUS  
Protocol, v 4.0 01 May  2020 AGS -v PLUS Mosquito Vax   
 
  
OCRPRO/DCR/NIAID/NIH  
CONFIDENTIAL  Page 11 of 67 PROTOCOL SUMMARY   
Full Title:   Randomized, Double -Blind, Placebo -Controlled, Single -
center, Phase 1 Study in Healthy Volunteers to Evaluate the 
Safety and Immunogenicity of AGS -v PLUS, a Universal 
Mosquito -Borne Disease and Mosquito Control Vaccine   
Short Title:  AGS -v PLUS Mosquito Vax   
IND Sponsor:   Office of Clinical Research Policy and Regulatory Operations  
Division of Clinical Research  
National Institute of Allergy and Infectious Diseases National 
Institutes of Health  
Laboratory of Infectious Diseases  
Clinical Studies Unit  
Conducted by:  [CONTACT_40679]:  [INVESTIGATOR_40613] B. Laurens , MD, MPH  
Sample Size  for Data 
Analysis : 50 participants  
Accrual Ceiling  for 
Vaccinees / Placebo 
Recipi[INVESTIGATOR_840] : 60 participants    
Study Population:  Healthy volunteers 18 to 50 years of age  
Accrual Period:  2 months  
Study Design:  This is a randomized, double -blind, placebo -controlled, 
single -center, Phase 1 study of AGS -v PLUS administered 
as 2 vaccinations before  a non -infected Aedes aegypti  and 
Aedes albopi[INVESTIGATOR_40614].  
 
Study Duration:  The study will begin approximately in April [ADDRESS_42339] been  collected  for all participant s. 
After unblinding, two follow -up safety calls will be carried out 
on all participants on days 181 and 366.  
Study Agents : 1012 µg of AGS -v PLUS  (50 nmol of each of the  five peptides 
in the formulation) non -adjuvanted, adjuvanted in Montanide 
ISA-51 or in Alhydrogel®. 
Study groups:  Group 1. saline placebo (day 1 and day 22) . 
Group 2. AGS -v PLUS non -adjuvanted (day 1 and day 22) . 
Group 3. AGS -v PLUS +  adjuvant Montanide ISA -51 (on day 
1) and saline placebo on day 22.   
Group 4. AGS -v PLUS  + adjuvant Montanide ISA -51 (on day 
1 and day 22) . 
 IND# [ZIP_CODE]  AGS -v PLUS  
Protocol, v 4.0 01 May  2020 AGS -v PLUS Mosquito Vax   
 
  
OCRPRO/DCR/NIAID/NIH  
CONFIDENTIAL  Page 12 of 67 Group 5. AGS -v PLUS  + Alhydrogel® adjuvant (on day 1 and 
day 22) . 
Intervention 
Description:  Individuals will be vaccinated subcutaneously with vaccine or 
placebo  21 days apart.  
Primary Objectives:  1. To determine the safety  and tolerability  of AGS -v PLUS 
when administered as two doses alone , or with  Montanide 
ISA-51 (single and  two doses) , or with Alhydrogel® (two 
doses) versus saline placebo  (two doses) . 
2. To measure specific  antibody and cellular  responses  in 
participants receiving two doses of AGS -v PLUS alone , or 
with Montanide ISA -51 (single and  two doses) , or with 
Alhydrogel® (two doses) versus saline placebo  (two doses) 
from pre -vaccination to post -vaccination .  
 
 Secondary Objectives:  1. To measure changes to the  antibody and cellular immune 
response s after clean Aedes aegypti  and Aedes albopi[INVESTIGATOR_40615] -v PLUS alone , or with Montanide ISA -51 (single and 
two doses) , or with Alhydrogel® (two doses)  versus saline 
placebo  (two doses) .  
2. To e valuate the effect of the AGS -v PLUS on Aedes 
aegypti  and Aedes albopi[INVESTIGATOR_40616] a nd 
fecundity after feeding on participants receiving two doses of 
AGS -v PLUS alone , or with Montanide ISA -51 (single and  
two doses) , or with Alhydrogel® (two dose s) versus saline 
placebo  (two doses) .  
 
Exploratory Objectives:  1. To evaluate reactions at the bite sites after mosquito 
feeding  on participants receiving two doses of AGS -v PLUS 
alone , or with Montanide  ISA-51 (one or two doses) , or with 
Alhydrogel® (two doses) versus saline placebo  (two doses) .   
2. To evaluate the effect of incubating Zika virus coated in 
vector saliva with peripheral blood mononuclear cells 
(PBMCs ) and/or serum collected from individuals receiving  
two doses of AGS -v PLUS alone , or with Montanide ISA -51 
(single and  two doses) , or with Alhydrogel® (two doses) 
versus receiving saline placebo  (two doses) . 
3. To evaluate cellular immune responses to Aedes aegypti , 
Aedes albopi[INVESTIGATOR_40617] -v 
PLUS a lone, or with Montanide ISA -51 (single and two 
doses), or with Alhydrogel® versus saline placebo (two 
doses) will be assessed from pre -vaccination (day 1) to post -
vaccination (day 43) and post -mosquito feeding (day 50).  
 IND# [ZIP_CODE]  AGS -v PLUS  
Protocol, v 4.0 01 May  2020 AGS -v PLUS Mosquito Vax   
 
  
OCRPRO/DCR/NIAID/NIH  
CONFIDENTIAL  Page 13 of 67  
Primary Endpoints:  1. Incidence an d severity of treatment emergent adverse 
events ( AEs) and serious adverse events ( SAEs ).  
2. Geometric mean titer and fold increase in s erum AGS -v 
PLUS specific immunoglobulin G ( IgG), immunoglobulin M 
(IgM) and immunoglobulin E ( IgE) titers from day 1 to day 43.  
3. Geometric mean concentration and fold increase in Type 
1 and Type 2 T -helper cell ( Th1 and Th2 ) cytokine responses 
(from day 1 to day 43) after in vitro  exposure of PBMCs with 
AGS -v PLUS antigens .  
Secondary Endpoints:  1. Geometric mean titer and the  fold increase in AGS -v PLUS 
specific IgG, IgM and IgE  titers seven days after mosquito 
feeding (day 50) compared to day 1 and day 43 titers . 
2. Geometric mean concentration and fold increase in AGS -
v PLUS specific Th1 and Th2 cytokine responses in the 
supernatants of PBMCs (day 50 compared to days 1 and 43) 
after in vitro  exposure with AGS -v PLUS . 
3. Survival and fecundity in Aedes aegypti  and Aedes 
albopi[INVESTIGATOR_40618] . 
 
Exploratory Endpoints:  1. Reactions to the mosquito bites by [CONTACT_40680]/papules, 
redness of the flare, swelling and itching [ADDRESS_42340] -
mosquito feeding (day 43), after 2 days (day 45) and after 7 
days (day 50) . 
2. Early innate immune response to the mosquito bites in 
AGS -v PLUS vaccinated participants compared to placebo 
from biopsies taken from the bite site [ADDRESS_42341] -feeding . 
3. In vitro viability of Zika virus coated in mosquito saliva after 
incubation with serum and/or PBMCs from vaccinated 
participants . 
4. Geometric mean concentration and fold increase in Th1 
and Th2  cytokine responses (from day 1 to day 43 , and from 
day 43 to day 50 ) after in vitro  exposure of PBMCs with 
mosquito saliva from Aedes aegypti , Aedes albopi[INVESTIGATOR_40619] . 
 
 
  
 IND# [ZIP_CODE]  AGS -v PLUS  
Protocol, v 4.0 01 May  2020 AGS -v PLUS Mosquito Vax   
 
  
OCRPRO/DCR/NIAID/NIH  
CONFIDENTIAL  Page [ADDRESS_42342] multiple arboviral and protozoal diseases.  
In addition , the vaccine potentially leads to a reduced mosquito lifespan after feeding therefore also 
reducing transmission of t hese diseases.  
In this protocol , we aim to demonstrate that the safety of AGS -v PLUS vaccine is  similar to SEEK’s first 
mosquito -borne disease vaccine, AGS -v, and other peptide -based vaccines (influenza vaccine [ FLU-v] 
and human immunodeficiency virus vaccine [ HIV-v]) that have shown  good safety profiles in previous 
Phase [ADDRESS_42343] time in the Americas on islands in the Caribbean. There is a risk that the virus will 
be imported to n ew areas by [CONTACT_40681] -to-person by [CONTACT_40682].  
A successful , universal mosquito -borne disease vaccine offer s the benefit of targeting emerging 
mosquito -borne disease s as well as the many established infections such as dengue , yellow fever  and 
malaria that make dealing with this newly emerging epi[INVESTIGATOR_901] a challenge.  
 
 IND# [ZIP_CODE]  AGS -v PLUS  
Protocol, v 4.0 01 May  2020 AGS -v PLUS Mosquito Vax   
 
  
OCRPRO/DCR/NIAID/NIH  
CONFIDENTIAL  Page [ADDRESS_42344] been reported 
in Africa, Asia and Europe and recently in 2013; the first outbreak in America was reported in the 
Caribbean islands.  
In large parts of Africa, South America and Asia, an estimated 3.2 billion people are at risk of contracting 
malaria1, and a rboviral infections occur worldwide without discrimination between developed and 
developi[INVESTIGATOR_40620].  Current prevention programs follow a two -prong ed approach simultaneously 
controlling mosquito populations by [CONTACT_40683] -treated mosquito nets to the population . For malaria, 
this approach, along with artemisinin -based combination therapy (ACT), has proven highly successful in 
locations such as Zanzibar2, but the effective implementation requires continuous investment by [CONTACT_40684], local governments, healthcare systems, and the people 
living in those communities. Unfortunately, this approach has not always been possible to sustain, as 
exemplified by [CONTACT_40685] 1950s -1960s3.  
Efforts in ma laria and arboviral elimination continue to include the development of an effective vaccine 
that can both prevent disease in a healthy individual (prophylactic vaccine) and block disease 
transmission from an infected individual to the insect vector (transm ission blocking vaccine). Most 
attempts at developi[INVESTIGATOR_007] a malaria vaccine have centered on the prophylactic application, but unfortunately 
they have shown little efficacy.  Even the most successful recent candidate vaccine, RTS,  S/AS01 
(RTS,S) by [CONTACT_40686], had vaccine efficacy of 27 -46% in children and infants, respectively4. Even 
if the RTS,S vaccine is licensed, there will be a recognized need for the continued implementation of 
current malaria prevention programs5.  
In this protocol , we propose to perform a Phase 1 study of a n improved , universal mosquito -borne disease 
vaccine manufactured by [CONTACT_40687].  SEEK sought to create an ideal malaria and arboviral disease vaccine that addresses both 
prophylactic and transmission -blocking components.  SEEK’s approach in developi[INVESTIGATOR_40621] a vaccine is 
defined by [CONTACT_40688]:   
  
 IND# [ZIP_CODE]  AGS -v PLUS  
Protocol, v 4.0 01 May  2020 AGS -v PLUS Mosquito Vax   
 
  
OCRPRO/DCR/NIAID/NIH  
CONFIDENTIAL  Page 16 of 67 • Because of complex and variabl e pathogen life cycle and antigenic make up, the vaccine 
prophylactic effect is not aimed at destroying the parasite itself, but rather at suppressing  
development of the essential physiologic environment that leads to succ essful human infection.  
• Because several  mosquito species are capable of pathogen transmi ssion , the vaccine 
transmission -blocking effect is not aimed at killing the vector on contact, but rather at prevent ing 
the very process of blood feeding which is esse ntial for successful vector procreation.  
• Because most nations where malaria and arboviral diseases are endemic have limited  healthcare 
delivery systems and budgets, the vaccine must be economically viable as a large -scale product 
entirely manufactured syn thetically from widely available raw components, and must not require 
complex storage and delivery systems.  
Female mosquitoes have an absolute physiological need for blood -feeding to produce viable eggs and a 
healthy offspring. As they probe the skin for blood with their proboscis they salivate into the bite site 
inoculating parasites (i.e. Plasmodium) or arbovirus (i.e., dengue virus, Zika virus) into their human host.   
Mosquito saliva contains a range of molecules including vasodilators, anticoagulants a nd 
immunomodulators whose purpose is to prevent the disruption of feeding by [CONTACT_40689]6. Mosquito saliva 
has been shown to inhibit T and B cell proliferation7 and downregulate the expression of interferon gamma 
(IFN-)8, a soluble  Type 1 T helper cell ( Th1) pro-inflammatory immune mediator known to have in vivo  
therapeutic and prophylactic effects against other arthropo d-transmitted diseases such as leishmaniasis9. 
Interestingly, mosquito saliva also triggers a non -inflammatory Type 2 T helper cell ( Th2) host immune 
response that causes the characteristic irritation and allergic reaction associated with mosquito bites10. 
With time and continuous exposure, individuals become desensitized to mosquito bites due to a reduction 
in Th2 cytokine mediators, thus allowing for a more effective devel opment of pro -inflammatory Th1 
responses11. Moreover,  exposure to bites from uninfected mosquitoes reduces the development of 
Plasmodium yoelii  in its murine host and that this protection is associated with a shift  to a Th1 response 
at the bite site after repeated exposure to mosquito saliva12.  
Research has shown that mosquito -injected sporozoites can remain at the bite site for at least [ADDRESS_42345] them (e.g., Leishmania  and Plasmodium ), 
but non -activated macrophages are unable to do so. Macrophage activation is characteristic of a Th1 
response and is inhibited by [CONTACT_40690]2 response triggered by [CONTACT_40691].  This same process of 
downregulati on of Th1 cytokines by [CONTACT_40692] a Th2 response at the bite 
by [CONTACT_40693]19, and 
arboviruses in general20.  
Beyond its direct effect on the parasite in the human host, an immune response to saliva has been shown 
to reduce malaria transmission. A monoc lonal antibody raised against a 100 kilodalton ( kDa) mosquito 
saliva ry gland protein significantly reduced the invasion by [CONTACT_40694]21. There is also evidence that antibodies 
against mos quito midgut and haemolymph antigens reduce the survival and fecundity of mosquitoes that 
fed on blood containing those antibodies22,23. Therefore, the antibodies against salivary antigens may 
 IND# [ZIP_CODE]  AGS -v PLUS  
Protocol, v 4.0 01 May  2020 AGS -v PLUS Mosquito Vax   
 
  
OCRPRO/DCR/NIAID/NIH  
CONFIDENTIAL  Page 17 of 67 block transmission of  these infections not only by [CONTACT_40695], but also by 
[CONTACT_40696].   
Based on the above scientific argument, SEEK’s approach to developi[INVESTIGATOR_007] a vaccine against mosquito -
borne pathogens based on identification of suitable antigenic targets in mosquito saliva capable of 
inducing, upon vaccination of the mammalian host, a strong anti -mosquito saliva Th1 response would (a) 
prevent pathogen infection and (b) block disease transmission by [CONTACT_40697] e arthropod vector’s 
salivary gland invasion and/or reduc ing vector survival and/or fecundity.  
As indicated earlier, SEEK manufactures  this vaccine by [CONTACT_40698]. However, 
mosquito saliva contains a multitude of proteins with molecular weights up to and above 100 kDa. 
Synthetic manufacturing of large proteins by 9-fluorenylmethoxycarbonyl  (FMOC)  chemistry is currentl y 
unfeasible. Therefore, SEEK first had to identify suitable vaccine targets in saliva for manufacturing. This 
process of target identification started with the simple separation of Anopheles gambiae salivary gland 
lysate proteins into fractions according to their molecular weight (i.e. <20 kDa, 20 -40 kDa, 40 -80 kDa and 
>80 kDa). These fractions were used to immunize mice upon which uninfected A. gambiae  mosquitoes 
were allowed to feed and the survival and fecundity of thes e mosquitoes analyzed. As shown in  Figure 
1, immunization with several mosquito salivary gland proteins fractions significantly reduced mosquito 
survival. The fraction con taining proteins below [ADDRESS_42346] effective, killing 80% of the 
mosquito population after only [ADDRESS_42347] -feeding. Fractions containing proteins between 20 and 40 kDa 
and over 80 kDa also reduced mosquito longevity, but were less effecti ve than the <20 kDa protein 
fraction. As Plasmodium  can complete its mosquito life -cycle stage in between 7 to 10 days, the ability 
of the <20 kDa protein fraction to kill 80% of mosquitoes within 6 days of feeding is important from the 
transmission blocki ng point of view as infected mosquitoes will die before they can transmit disease.   
 
 
 
Figure 1. Mosquito survival.  
Graph representing the mosquito % survival after feeding on mice immunized with different salivary gland protein fractions 
(vehicle (control), <20 kDa, 20 -40 kDa, 40 -80 kDa and >80 kDa). Mosquito salivary glands were dissected and their protein 
content sep arated by [CONTACT_451] -PAGE according to their molecular weight  (MW) . Proteins within the MW ranges of interest were 
recovered from the gel and used to immunize mice. Fresh A. gambiae  mosquitoes fed on these mice and were monitored for [ADDRESS_42348] -feed for survival  (N=150 mosquitoes per group).  

 IND# [ZIP_CODE]  AGS -v PLUS  
Protocol, v 4.0 01 May  2020 AGS -v PLUS Mosquito Vax   
 
  
OCRPRO/DCR/NIAID/NIH  
CONFIDENTIAL  Page 18 of 67 In addition, immunization with the <20 kDa fraction, and the 20 -40 kDa fraction significantly (p<0.05) 
reduced the number of eggs produced, eggs laid, larvae arising from eggs and mature adult offspring by 
[CONTACT_40699] ( Figure 2).  
           
Figure 2. Effect of immunization with salivary gland protein fractions on mosquito fecundity.  
Vehicle (control), <20KDa, 20 -40KDa, 40 -80KDa and >80KDa.  
 
Such reduction in the number of viable offspring would have a significant effect on the number of vectors 
available for disease transmission at any one time and hence in the overall disease transmission ra te.  
From this point, SEEK proceeded to identify the proteins present in the fractions containing proteins <[ADDRESS_42349] of the se proteins were still too large to be chemically 
synthesized and hence further work was required to identify reactive domains in these proteins that could 
successfully be manufactured and still retain the desired immunogenicity. This stage of the process was 
carried out using a computer algorithm developed by [CONTACT_40700]. The algorithm identifies and categorizes T -
cell epi[INVESTIGATOR_40622] a protein based on analysis of the structural affinity of a peptide for a given major 
histocompatibility complex/human leukocyte a ntigen ( MHC/HLA ) allele and the reactivity of this complex 
to T-cells. Any small regions (25+ amino acids) within a protein identified by [CONTACT_40701] T-cell epi[INVESTIGATOR_40623] -referenced against all available human proteomic data (GeneBank 
and Swiss -Prot). Any region showing significant sequence similarity was discarded to minimize the risk 
of inducing an autoimmune challenge following immunization. This algorithm and approach have already 
been successfully applied to the identific ation of conserved reactive T-cell regions in both influenza virus24 
and human immunodeficiency virus ( HIV). The identified sequences constitute two independent 
candidate vaccine preparations that have been tested clinical trials ([STUDY_ID_REMOVED], [STUDY_ID_REMOVED], 
[STUDY_ID_REMOVED], [STUDY_ID_REMOVED], [STUDY_ID_REMOVED]) .  

 IND# [ZIP_CODE]  AGS -v PLUS  
Protocol, v 4.0 01 May  2020 AGS -v PLUS Mosquito Vax   
 
  
OCRPRO/DCR/NIAID/NIH  
CONFIDENTIAL  Page 19 of 67 The selection of reactive T-cell regions is based on SEEK’s interest in inducing a specific Th1 response 
to the salivary proteins. As indicated earlier in this document, a switch from a Th2 to a Th1 immune 
response to mosquito vector saliva is associated with resistance and natural immun ity to malaria 
infection.  
Several reactive regions in salivary proteins of <40 kDa each containing multiple T-cell epi[INVESTIGATOR_40624] F MOC  chemistry. A  cocktail of these small protein -sequences (all less t han 
8 kDa),  identified as AGS -v (or AGS -mix), were used to immunize mice and to establish the type of 
induced immune response. While multiple  peptides may not be  needed, the rationale is that the vaccine 
was developed to be active against a range of hematophagous art hropod vectors (such as Anopheles  
and Aedes  mosquitos). As shown in Figure 3, immunization with AGS -v induced a strong IFN - response 
from immune cells upon recall with t he antigen compared to immunization with a control mix of irrelevant 
peptides.  
 
 
 
 
Immunization with AGS -v was also found to induce a strong antibody response to the vaccine candidate 
(Figure 4), characterized by a significant contribution by [CONTACT_40702]2a isotype. Both IFN - and 
IgG2a  are considered primary mediators of a Th1 response and hence immunization with AGS -v can and 
does induce the desired Th1 response  in mice .  
 
 
              Figure 3. IFN  response in mice with AGS -mix (AGS -v) or vehicle  
 IND# [ZIP_CODE]  AGS -v PLUS  
Protocol, v 4.0 01 May  2020 AGS -v PLUS Mosquito Vax   
 
  
OCRPRO/DCR/NIAID/NIH  
CONFIDENTIAL  Page 20 of 67     
  
 
Having established that immunization with AGS -v induces a Th1 response in mice, SEEK wanted to 
establish whether this response was able to reduce the rate of malaria infection in a mouse model.   
Traditional experimental models of malaria infection rely on intravenous  (IV) injection of large numbers 
of parasites to successfully establish infection in the mouse. It has been reported that these models do 
not reflect the natural process of infection by [CONTACT_930] b ite in which parasite numbers several orders of 
magnitude lower than those used in the experimental models are capable of successfully inducing 
infection25. Interestingly, it has been suggested by [CONTACT_40703], which having been shown to be 
very effective in such models, did not induce any significant protection when tested in real -life infection 
conditions. It is for this very reason and the nature of the vaccine candidate that SEEK chose to test the 
product in a natural model of infection (i.e. via the bite of infected mosquitoes).  
Preliminary studies using a natural model of infection involving A. gambiae  infected with P. yoelii 
nigeriensis  show ed that mice vaccinated with AGS -v wer e more resilient to infection than mice vaccinated 
with an irrelevant peptide control mix ( Figure 5). AGS -v was found to reduce infection rates 4 -fold 
compared to the control group.   
 
 
 
 
 
 
 
  
Antibodies response to AGS -mix 
-0.5 
0 
0.5 
1 
1.5 
2 
2.5 
3 
3.5 
1:100 
 1:200 
 1:400 
Mouse sera dilution  
Abs 450nm  
 AGS -mix immunised total Ig  
AGS -mix immunised IgG2a  
vehicle immunised total Ig  
vehicle immunised IgG2a  
Figure 4. Total Ig and IgG2a AGS -mix (AGS -v)-specific antibody responses in mice meas ured by [CONTACT_6428].  
 IND# [ZIP_CODE]  AGS -v PLUS  
Protocol, v 4.0 01 May  2020 AGS -v PLUS Mosquito Vax   
 
  
OCRPRO/DCR/NIAID/NIH  
CONFIDENTIAL  Page 21 of 67           
 
 
  
 
 
Further experiments in C57BL6, BALBc, and CD1 were  performed to measure immunogenicity. All had 
good responses to the vaccine after two weeks, and antibodies t o AGS -v were  raised to the vaccine 
antigens. T -cell responses we re seen two weeks after vaccination .  
SEEK carried out clinical trials with two additional vaccines developed using the same technology as with 
AGS -v and AGS -v PLUS . Based on their experience with influenza vaccine ( FLU-v) and human 
immunodeficiency virus vaccine ( HIV-v) in clinical trials it is clear that a combination of four  to five  
peptides allows the immune system to mount a response without peptid es competing with each other. 
These studie s have also assisted to determin e an appropriate dose . For these vaccines, [ADDRESS_42350] immunogenic dose and replicated the ratio nmol/Kg in mouse 
studies . In phase 1 studies , a single dose of 25 nmol or 50nmol  of FLU -v or HIV -v with and without 
adjuvant were given to approximately 10 participant s in each arm.  In the HIV -v phase 1 trial, both dose s 
induced a significant and sustained antibody response in 60% of volunteers but on ly the higher 50nmol  
dose produced a significant vaccine -specific cellular response in approximately 50% of volunteers. In 
FLU-v phase 1 trial, both adjuvanted doses produced a significant IFN - response in more than 80% of 
volunteers in a dose -dependent m anner. Three FLU-v phase [ADDRESS_42351] -vaccination with two doses of a Non Relevant Peptide (NRP) mix or AGS -v 15 days 
apart.  

 IND# [ZIP_CODE]  AGS -v PLUS  
Protocol, v 4.0 01 May  2020 AGS -v PLUS Mosquito Vax   
 
  
OCRPRO/DCR/NIAID/NIH  
CONFIDENTIAL  Page 22 of 67 The National Institute of Allergy and Infectious Diseases (NIAID) – National Institutes of Health (NIH) , in 
collaboration wi th SEEK, has performed a phase 1 clinical study testing the safety, immunogenicity and 
in vitro  efficacy of AGS -v administered as two doses non -adjuvanted or adjuvanted in Montanide ISA -51 
compared to placebo  (NCT 03055000) . Investigators identified no  safety concerns to date . 
SEEK has manufactured an  improved AGS -v vaccine named AGS -v PLUS. This new formulation 
contains the exact four peptides included in AGS -v with the addition of a fifth peptide that provides higher 
antibody titer and increases the brea dth of protection as the protein of origin is f ound in the saliva of many 
mosquitoes such as Anopheles gambiae, Anopheles darling, Culex quinquefasciatus, Aedes aegypti and 
Aedes  albopi[INVESTIGATOR_40625] s. 
Preclinical i mmunogenicity data studies show that AGS -v PLUS is capable of inducing strong Th1 
responses measure d as IFN - secretion after in vitro  exposure of splenocytes from vaccinated mice to 
the vaccine antigens (Figure 6). Even when AGS -v PLUS is formulated with an adjuvant b iased towards 
inducing Th2 responses such as Alhydrogel®, a strong IFN - secretion is detected.  
 
 
Figure 6. IFN- secretion by [CONTACT_40678] -v PLUS formulated in 
different adjuvants (Montanide ISA -51, Alhydrogel® and Adju -phos).  
 
 
AGS -v PLUS is also capable of inducing high titer s of antigen -specific IgG antibodies  (Figure 7) when 
administered as two subcutaneous doses 21 days apart fo rmulated in different adjuvants;  an oil in water 
emulsion (Montanide ISA -51) or as a suspe nsion with alum based adjuvants ( Alhydrogel® and Adju-
phos). 
 

 IND# [ZIP_CODE]  AGS -v PLUS  
Protocol, v 4.0 01 May  2020 AGS -v PLUS Mosquito Vax   
 
  
OCRPRO/DCR/NIAID/NIH  
CONFIDENTIAL  Page [ADDRESS_42352] AGS -v PLUS or the single peptides in the serum (1:400) of mice 
vaccinated with Placebo or AGS -v PLUS formulated in Montanide ISA -51, Alhydrogel®  or Adj u-phos 
adjuvants at pre -vaccination (day 0) and post -vaccination (day 42). Y axis=corrected absorbance, X -axis= 
vaccination received.  
 
As seen in Figure 7, the fifth peptide in the AGS -v PLUS formulation, AGS -20, induces strong antibody 
responses with all adjuvants tested confirming that addition of this peptide will increase the overall 
antibody responses to AGS -v PLUS.  
In addition to testing two doses of AGS -v PLUS  in the different formulations , replicating the groups f rom 
the SPI[INVESTIGATOR_40626] ( Phase 1 study with AGS -v), the vaccine will also be tested as a single dose in Montanide 
ISA-51. Animal data showed that ISA -51 was the only a djuvant tested that induced an increase  in the 
antibody response after a single dose  (Figure 8). A single -dose vaccine will always have better 
compliance than one that requires two doses.  
 

 IND# [ZIP_CODE]  AGS -v PLUS  
Protocol, v 4.0 01 May  2020 AGS -v PLUS Mosquito Vax   
 
  
OCRPRO/DCR/NIAID/NIH  
CONFIDENTIAL  Page [ADDRESS_42353] AGS -v of mice vaccinated with Placebo or AGS -v PLUS formulated in 
Montanide ISA -51, Alhydrogel® or Adju -phos adjuv ants at pre -vaccination (day 0), [ADDRESS_42354] dose 
(day 21) and 21 days after the second dose (day 42) . Y axis=corrected absorbance, X -axis= vaccination 
received.  
 
In summary, the data presented here supports the validity of SEEK’s scientific hypothesis that 
immunization with mosquito salivary antigens can induce a Th1 sp ecific response to provide both 
prophylactic and transmission blocking immunity. Other groups have shown the ability of vaccination with 
salivary proteins from sand flies to reduce  infection in diseases such as L eishmaniasis26,27. SEEK’s 
vaccine is composed entirely of synthetic products that do not require complex heterologous expression 
systems for manufacture and hence can be readily scaled up to accommodate for large scale demand. 
The composition and application  of these synthetic products are the subject of a patent by [CONTACT_40700].  
The AGS -v PLUS preparation is a vaccine candidate capable of acting  on both the prophylactic and 
transmission blocking areas of malaria and arbovirus infection control. Moreover, it is a universal vaccine 
as it does not target a single pathogen but the vectors that transmit multiple pathog ens, both viral and 
protozoal. These vectors are hematophagous arthropods and are dependent on the immunomodulatory 
activities of arthropod saliva to achieve successful infection of the host20. This is particularly relevant 
since many hematophagou s arthropods such as Aedes aegypti  transmi t more than one pathogen (e.g. 
dengue, Zika and West Nile virus).  
In this protocol we plan to demonstrate that the safety of this vaccine is similar to SEEK’s other peptide 
based vaccines  (AGS -v, FLU -v and HIV -v) that have been found to have very good safety profiles in 
Phase [ADDRESS_42355] of the world, a successful universal 
mosquito -borne disease vaccine offers the benefit of targeting this emerging disease as well as the many 
established infections such as  dengue , yellow fever  and malaria .  
  

 IND# [ZIP_CODE]  AGS -v PLUS  
Protocol, v 4.0 01 May  2020 AGS -v PLUS Mosquito Vax   
 
  
OCRPRO/DCR/NIAID/NIH  
CONFIDENTIAL  Page 25 of 67 2  Study Objectives  
 
2.1  Primary Objective   
The primary objectives of the study are:  
1. To determine the safety of and tolerability of AGS -v PLUS  when administered as two doses 
alone , or with Montanide ISA -51 (single an d two doses) , or with Alhydrogel® (two doses)  
versus salin e placebo (two doses) .  
2. To measure specific antibody and cellular responses in participants receiving two doses of 
AGS -v PLUS alone , or with Montanide ISA -51 (single and  two doses) , or with Alhydrogel® 
(two doses) versus saline placebo (two doses) from pre -vaccination to post -vaccination .  
A previous study tested 2 doses of AGS -v, 21 days apart, as non -adjuvanted or in Montanide. 
For continuation, AGS -v plus will be tested with the same formu lation as AGS -v but also with 
a different adjuvant, Alhydrogel®. In addition, a single dose of AGS -v plus in Montanide will be 
tested as animal data showed that only Montanide can trigger an antibody response to AGS -
v after a single dose.  In order to keep the blinding, participant s in this group will receive saline 
on day 22.  
2.2  Secondary Objectives  
The secondary objectives of this study are :   
1. To measure changes to the antibody and cellular immune responses after clean Aedes 
aegypti  and Aedes albopi[INVESTIGATOR_40627] -
v PLUS alone , or with Montanide ISA -51 (single and  two doses) , or with Alhydrogel® (two 
doses) versus saline placebo  (two doses) .  
2. To evaluate the effect of the AGS -v PLUS on Aedes aegypti  and Aedes albopi[INVESTIGATOR_40628] -v PLUS alone , 
or with Montan ide ISA -51 (single and  two doses) , or with Alhydrogel® (two doses) versus 
saline placebo  (two doses) .  
 
2.3  Exploratory Objectives   
 
1. To evaluate reactions at the bite sites after mosquito feeding  on participants receiving two 
doses of AGS -v PLUS alone , or with Montanide ISA -51 (one or two doses) , or with Alhydrogel® 
(two doses) versus saline placebo  (two doses) .   
2. To evaluate the effect of incubating Zika virus coated in vector saliva with peripheral blood 
mononuclear cells ( PBMCs ) and/or serum collected from individuals receiving  two doses of  
AGS -v PLUS alone , or with Montanide ISA -51 (single  and two doses) , or with Alhydrogel® 
(two doses) versus receiving saline placebo (two doses).  
3. To evaluate cellular immune responses to Aedes aegypti , Aedes albopi[INVESTIGATOR_40629] -v PLUS 
alone, or with Montanide ISA -51 (single and two doses), or with Alhydrogel® ve rsus saline 
 IND# [ZIP_CODE]  AGS -v PLUS  
Protocol, v 4.0 01 May  2020 AGS -v PLUS Mosquito Vax   
 
  
OCRPRO/DCR/NIAID/NIH  
CONFIDENTIAL  Page 26 of 67 placebo (two doses) will be assessed from pre -vaccination (day 1) to post -vaccination (day 
43) and post -mosquito feeding (day 50).  
3  Study Design  
 
3.1  Description of the Study Design  
This is a randomized, double -blind, placebo -controlled, single -center, Phase 1 study of AGS -v PLUS 
administered at Day s 0 and 21 before  Aedes aegypti  and Aedes  albopi[INVESTIGATOR_40630]  43. 
Participants will be randomized 1:1:1 :1:1 to:  
• Group 1: Saline p lacebo (N=10) on day 1  and day 2 2. 
• Group 2: 1012  µg (5 0 nmol each peptide) unadjuvanted AGS -v PLUS vaccine (N=1 0) on day  1 
and day 22 . 
• Group 3: 1012  µg (50 nmol each peptide) Montanide ISA -51 adjuvanted AGS -v PLUS vaccine 
(N=1 0) on day 1 a nd saline placebo on day 22 . 
• Group 4: 1012  µg (50 nmol each peptide) Montanide ISA -51 adjuvanted AGS -v PLUS vaccine 
(N=1 0) on day 1 and day 22 . 
• Group 5: 1012  µg (50 nmol each peptide) Alhydrogel® adjuvanted AGS -v PLUS vaccine  (N=1 0) 
on day 1 and day 22 . 
 
A placebo control will be used to establish the frequency and magnitude of changes in endpoints that 
may occur in the absence of active vaccination. Randomization will be used to minimize bias in the 
assignment of participants to vac cination groups, to increase the likelihood that known and unknown 
participant attributes (e.g., demographic and baseline characteristics) are evenly balanced across 
vaccination groups, and to enhance the validity of statistical comparisons across vaccinat ion groups. 
Blinding of participants and the study team will be used to reduce potential bias during data collection 
and evaluation of endpoints.   
The study will be unbl inded once all the data for the primary and secondary endpoints and safety data 
up to d ay [ADDRESS_42356] been collected. Otherwise, the blind should be broken only if specific emergency 
treatment/course of action would be dictated by [CONTACT_40704]. In such 
cases, the investigator may in an emergency determine the  identity of the vaccine by [CONTACT_40705]. It is recommended that the investigator contact [CONTACT_40706], before breaking the blind. In the event the blind is broken, the sponsor must be 
informed as soon as possible. Accidental unblinding (e.g. if the investigator sees the investigational 
product [ IP] administration logs) must be reported within [ADDRESS_42357] be documented in the 
source document.  
  
 IND# [ZIP_CODE]  AGS -v PLUS  
Protocol, v 4.0 01 May  2020 AGS -v PLUS Mosquito Vax   
 
  
OCRPRO/DCR/NIAID/NIH  
CONFIDENTIAL  Page 27 of 67 3.2  Study Endpoints  
Primary:    
1. Incidence and severity of treatment emergent adverse events (AEs ) and serious adverse 
events ( SAEs ).  
2. Geometric mean titer and  fold increase in s erum  AGS -v PLUS  specific immunoglobulin G 
(IgG), immunoglobulin M ( IgM) and immunoglobulin E ( IgE) titers from day 1 to day 43. 
3. Geometric mean concentration  and fold increase in Th1 and Th2 cytokine responses  (from 
day 1 to day 43)  after in vitro exposure of PBMCs with AGS -v PLUS antigens . 
 
Secondary:  
1. Geometric mean titer and fold increase in AGS -v PLUS specific IgG, IgM and IgE  titers seven 
days after mosquito feeding  (day 50) compared to day 1 and 43 .  
2. Geometric mean concentration and fold increase in AGS -v PLUS specific Th1 and Th2 
cytokine responses in the supernatants of PBMCs  (day 50 compared to days 1 and 43) after 
in vitro  exposure with AGS -v plus . 
3. Survival and fecundity in Aedes aegypti  and Aedes albopi[INVESTIGATOR_40631] s. 
 
Exploratory:  
1. Reaction s to mosquito bite s by [CONTACT_40680]/papules, redness of the flare, swelling and 
itching [ADDRESS_42358] -mosquito feeding  (day 43) , after two days (day 45) and  after 7 days (day 
50). 
2. Early innate immune response to the mosquito bites in AGS -v PLUS vaccinated participants 
compared to placebo from biopsies taken from the bite site [ADDRESS_42359] -feeding . 
3. In vitro  viability  of Zika virus coated in mosquito saliva after incubation with serum and/or 
PBMCs from vaccinated participants.   
4. Geometric mean concentration and fold increase in Th1 and Th2 cytoki ne responses (from 
day 1 to day 43, and from day 43 to day 50) after in vitro  exposure of PBMCs with mosquito 
saliva from Aedes aegypti , Aedes albopi[INVESTIGATOR_40632] . 
 
 
[ADDRESS_42360] (IRB) approval. Educational meetings will be offered to the public both 
within and outside the university system for the purposes of informing individuals of the stu dy. Every effort 
 IND# [ZIP_CODE]  AGS -v PLUS  
Protocol, v 4.0 01 May  2020 AGS -v PLUS Mosquito Vax   
 
  
OCRPRO/DCR/NIAID/NIH  
CONFIDENTIAL  Page 28 of 67 will be made to achieve a balanced participant population while avoiding the enrollment of vulnerable 
populations. Careful screening will be conducted to avoid enrollment of individuals with substance abuse 
or psychiatric difficulties. Eff orts to retain study participants include, but are not limited to: development 
of professional rapport with potential participants, obtaining valid contact [CONTACT_40707], and telephone reminder calls and/or emai l reminders for upcoming study 
visits.  
 
The Center for Vaccine Development  and Global Health  (CVD) will be the site for participant  enrollment  
and inoculation . Mosquito feedings will occur in the Malaria Challenge Suite, where studies of controlled 
human m alaria infection take place. O utpatient follow -up will be conducted at  the CVD outpatient clinic . 
 
4.1 Inclusion Criteria  
1. Healthy women and men who are ≥18 and ≤50 years of age.  
2. Willingness to complete all study visits and comply with all study requirements.  
3. A male participant  is eligible for the study if he agrees to practicing abstinence or using a condom 
with spermicide plus an acceptable form of contraception (see inclusion c riteria 4) being used by 
[CONTACT_40708] [ADDRESS_42361] feeding and 1 of the 
following:  
• Of non -child bearing potential (i.e., women who have had a hysterectomy or tubal ligation , or 
are postmenopausal, as defined by [CONTACT_40709] ≥1 year).  
• Of childbearing potential but agrees to practice effective contraception or abstinence for 4 
weeks before  study  initiation and 12 weeks after the second vaccine administration. 
Acceptable methods of contraception include  a female partner who is the sole sexual partner 
of the female participant,  a male partner who is sterile and is the sole sexual partner of the 
female participant , or a male partner who uses a condom with spermicide plus 1 or more of 
the following: 1) implants of levonorgestrel; 2) injectable progestogen; 3) an intrauterine 
device with a documented failure rate of <1%; 4) oral contraceptives; and 5) double barrier 
method including diaphragm.  
5. Willing to have samples stored for future research .  
6. Agrees to abstain from alcohol intake for 24 hours before  each study visit.  
7. Agrees to not donate blood or blood products throughout the study.   
8. Score >70% on comprehension quiz at screening  
 
4.4  Exclusion Criteria   
1. Participant has any underlying or current medical condition, which, in the opi[INVESTIGATOR_684], would interfere with the participation in the study.   
 IND# [ZIP_CODE]  AGS -v PLUS  
Protocol, v 4.0 01 May  2020 AGS -v PLUS Mosquito Vax   
 
  
OCRPRO/DCR/NIAID/NIH  
CONFIDENTIAL  Page 29 of 67 2. Individual with body mass index (BMI) ≤18 and ≥40.   
3. Participants who have a clinically significant (as determined by [CONTACT_978]  [INVESTIGATOR_1461] ) baseline Grade 
1 or greater toxicity, or any Grade 2 or greater toxicity (regardless of clinical significance) by [CONTACT_40710].  
4. Receipt of blood or blood products including immunoglobulin within 3 months before  enrollment.  
5. Receipt of any unlicensed drug within 3 months or 5.5 half -lives (whichever is greater) before  
enrollment.  
6. Receipt of any unlicensed vaccine wi thin 6 months before  enrollment.  
7. Partic ipated in study [STUDY_ID_REMOVED]  testing safety and immunogenicity of AGS -v. 
8. Self-reported or known history of alcoholism or drug abuse within 6 months before  enrollment .  
9. Self-reported or known history of psychiatric or psychological issues that require treatment and are 
deemed by [CONTACT_978] [INVESTIGATOR_40633] a contraindication to protocol participation.   
10. History of a previous severe allergic reaction with generalized urticaria , angioedema, anaphylaxis 
or anaphylactoid reaction.  
11. Any condition or event that, in the judgment of the PI  [INVESTIGATOR_1461] , is a contraindication to protocol 
participation or impairs the volunteer’s ability to give informed consent.  
12. Known allergy to any vaccine component , including adjuvants . 
13. History of severe immunization reaction.  
14. Severe allergic reaction to mosquito bites  (anaphylaxis)   
15. Have taken oral or parenteral (including intra -articular) corticosteroids of any dose within 
[ADDRESS_42362] taken high -dose inhaled corticosteroids * within 30 days before each study vaccination  
17. Received or plan to receive a licensed , live vaccine within 30 days before or after  the study 
vaccination  
18. Received or plan to receive a licensed, inactivated vaccine within 14 days before or after study 
vaccination  
19. Serologic evidence of infection with  HIV, hepatitis B virus, or hepatitis C virus  
20. Ongoing chronic skin condition, or acute skin condition at the time of vaccination or mosquito 
feeding , except for mild eczema . 
21. History of keloid formation  after previous biopsies, lacerations, abrasions, surgeries, or other 
skin procedures (e.g., cosmetic pi[INVESTIGATOR_2982]) that are deemed by [CONTACT_978] [INVESTIGATOR_40633] a 
contraindication to protocol participation.  
 IND# [ZIP_CODE]  AGS -v PLUS  
Protocol, v 4.0 01 May  2020 AGS -v PLUS Mosquito Vax   
 
  
OCRPRO/DCR/NIAID/NIH  
CONFIDENTIAL  Page 30 of 67 22. Pregnancy, breastfeeding, or planning to become pregnant up to one month after mosquito 
feeding.  
* High -dose defined per age as using inhaled high dose per reference chart 
https://www.nhlbi.nih.gov/sites/default/files/media/docs/asthma_qrg_0_0.pdf  
  
Co-enrollment Guidelines: Co-enrollment in other trials is restricted  and discouraged , but may take 
place with the approval of the PI [INVESTIGATOR_40634]. Limitations of total blood volume 
collection between the two studies must conform with  NIH limits on blood collection.  
4.5  Justification for Exclusion of Pregnant Women and Children (Special Populations)  
In this study, an investigational vaccine will be administered to the participants. Therefore, children, 
pregnant women, and other individuals at high risk of complications will be excluded as the risk to these 
individuals may be increased. In addition, the investigational vaccine has not undergone preclinical 
reproductive safety testing .  
  
Participants younger than 18 years of age will b e excluded from the study. Because there are insufficient 
data regarding dosing or AEs available in adults to judge the potential risk in children, the study is of 
“greater than minimal risk” and does not meet the criterion of 45 Code of Federal Regulation s (CFR) 46, 
Subpart D, governing the participation of children in research.  
4.6 Reasons for Withdrawal  
Participants are free to withdraw from the study at any time. Participants will be encouraged to remain in 
the study to be followed for safety purposes.   
 
A study participant  will be discontinued from participation in the study for  any one of the following reasons : 
• Request by [CONTACT_40711];  
• Loss to follow -up; 
• Request of primary care provider;  
• At the request of the IRB/Ethics committee, NIH , NIAID, or the U.S. Food and Drug 
Administration (FDA); 
• The participant ’s well -being, based on the opi[INVESTIGATOR_871] . 
Because a true intent -to-treat analysis requires the inclusion of all participants enrolled to the extent 
possible, this requires an intent -to-treat design in which all participants are followed according to the pre -
specified schedule with primary, and perhaps secondary, outcome assessments, regardless of 
compliance, adverse effects, or other post -enrol lment observ ations — participant refusal exce pted.  
 
4.7 Handling of Withdrawals  
If voluntary withdrawal occurs, the participant  will be asked for permission to continue scheduled 
evaluations, complete an end -of-study evaluation, and be given appropriate car e under medical 
 IND# [ZIP_CODE]  AGS -v PLUS  
Protocol, v 4.0 01 May  2020 AGS -v PLUS Mosquito Vax   
 
  
OCRPRO/DCR/NIAID/NIH  
CONFIDENTIAL  Page 31 of 67 supervision until the symptoms of any adverse event resolve or until the participant ’s condition becomes 
stable.  
It is vital to collect safety data on any participant  discontinued because of an AE or SAE, and every effort 
will be made to u ndertake protocol -specified safety follow -up procedures. Participant s will follow early 
termination procedures if withdrawn.  
 
4.8 Termination of Study  
The study may be discontinued due to the development of laboratory toxicities, at the discretion of the 
FDA or Division of Microbiology and Infectious Diseases  (DMID ), or due to natural disaster.  
 
 
5  Study Agents/Interventions  
 
5.1 Description  
5.1.1 AGS -v PLUS  
AGS -v PLUS contains five  peptides, or drug substances: AGS -6, AGS -20, AGS -30, AGS -31, and AGS -
35. Each peptide consist s of 32 to 44 amino acids. They are chemical ly synthesized and available as 
acetate salts. The peptides contain multiple T -cell reactive regions capable of inducing Th1 responses.  
  
A solution of the f ive drug substances (50 nmol net peptide/g of each drug substance) is prepared by 
[CONTACT_40712] 50% acetic acid . The five solubilized peptides are mixed to 
make up AGS -v PLUS bulk solution. This mix is filter -sterilized before f illing glass vials automatically with 
the sterile AGS -v PLUS bulk solution by [CONTACT_40713] 1012  g of AGS -v PLUS solution per vial . 
The vials are then lyophilized to remove the water and acetic acid used in the compounding  whereupon 
a relatively  neutral pH, suitable for human injection, will be achieved after reconstitution. The vials are 
sealed and stored at -20oC. 
  
Bottle labels bear the appropriate label text , includ ing the caution statement: "Caution: New Drug – 
Limited  by [CONTACT_4496] (or [LOCATION_002]) law to investigational use ," as required by [CONTACT_40714].  Any addition or modification to the label apart from the variable data must be authorized by [CONTACT_40715].  
5.1.2 Adjuvants  
The adjuvants used are Montanide ISA -51 and Alhydrogel®. 
 
Montanide ISA -51, manufactured by [CONTACT_40716] ([LOCATION_009]), is a mixture of oil and water that when combined 
with an antigen (such as a vaccine) it boosts the response to that antigen.  It is comprised of two raw 
materials Drakeol 6 VR as a min eral oil and mannide monooleate as the surfactant28. Drakeol 6 VR is a 
mineral oil with [LOCATION_002] Pharmacopeia/European Pharmacopeia ( USP/EP ) monograph. It is a 
mixture of several hydrocarbons with different le ngth obtained from petroleum. Drakeol 6 VR stays at the 
injection site and is progressively eliminated by [CONTACT_40717] t-cells such as macrophages. It can also be 
partially metabolized into fatty acids, triglycerides, phospholipi[INVESTIGATOR_805], or sterols. 30% of the miner al oil 
disappears during the first month and the majority of the oil found outside the injection site is in the liver 
 IND# [ZIP_CODE]  AGS -v PLUS  
Protocol, v 4.0 01 May  2020 AGS -v PLUS Mosquito Vax   
 
  
OCRPRO/DCR/NIAID/NIH  
CONFIDENTIAL  Page 32 of 67 and fatty tissues in the form of phospholipi[INVESTIGATOR_40635]28. Mannide monooleate is a non -ionic 
surfactant based on oleic acid and sugar. Oleic acid is a distribution of various fatty acids with a 
predominant species C18'.  30-40% of mannide monooleate is removed from the injection site after 
24 hours. After 3 months, 30% of the surfactant still remains28. Montanide ISA [ADDRESS_42363] led to toxicities with other versions of 
Incomplete Freund’s adjuvant ( IFA) in the past.  It also uses a different ratio of emulsifier to oil resulting 
in a more consistent and controllable emulsion.  It has been used in multiple vaccine trials including those 
for malaria28.  
 
Alhydrogel® (Croda Denmark)  is a sterilized , aluminium hydroxide wet gel suspension which has been 
tested free of pyrogenicity. It tolerates re -autoclavation, but is destroyed if frozen.  When the pH is 
maintained at 5 -7, which is normal during vaccine production, Alhydrogel® has a pos itive charge so it 
readily adsorb s negatively charged antigens (e.g. proteins with acidic isoelectric points kept at neutral 
pH). Alhydrogel® improves attraction and uptake of antigen by [CONTACT_22653] (APCs) by 
[CONTACT_40718]. This improves Th2 antibody production 
specific to the antigen. Alhydrogel® adjuvant has been u sed in multiple commercial vaccine formulations29 
with a 40+ year history of safe and effective use.  
 
5.1.3 Placebo  
The placebo contains sterile saline  for injection  only.  
 
5.2 Study Agent s Storage and Stability  
The vials of water for injection ( WFI), 0.09 normal saline, Monta nide ISA -51 and Alhydrogel® should be 
stored at room temperature  (15-30⁰C).  
AGS -v PLUS must be stored at ≤-20oC (±5 oC). AGS -v PLUS is expected to be stable for at least 
24 months at this temperature . Stability testing will be performed to cover the duration of the trial. The 
four peptide formulation ( AGS -v) was tested for stability up to 6  months at +25oC 60%RH, 12 months at 
+5oC and [ADDRESS_42364] ogel®, 
saline ampoules and WFI ampoules should be stored at room temperature ( 15-30°C).  
No study drug can be dispensed beyond the expi[INVESTIGATOR_320].   
 
5.3  Preparation  
• Please see pharmacy manual for specifics regarding study product preparation . 
  
5.4  Dosing and Administration   
Participant s will be randomized to one of the following vaccination regimens:  
  
• Group 1: two doses (day s 1 and 2 2) saline (0.5  mL) 
 IND# [ZIP_CODE]  AGS -v PLUS  
Protocol, v 4.0 01 May  2020 AGS -v PLUS Mosquito Vax   
 
  
OCRPRO/DCR/NIAID/NIH  
CONFIDENTIAL  Page 33 of 67 • Group 2: two doses ( days 1 and 22 ) non -adjuvanted AGS -v PLUS (50 nmol each peptide) as a 
suspensi on in 0.5 mL WFI. 
• Group 3: one dose (day 1) of AGS -v PLUS (50 nmol each peptide) in 0.25  mL of adjuvant 
Montanide ISA -51 emulsified in 0.25  mL of WFI and one dose of saline placebo (0.5  mL) on 
day 22 
• Group 4 : two doses ( days 1 and 22 ) of AGS -v PLUS (50 nmol each peptide) in 0.25  mL of adjuvant 
Montanide ISA -51 emulsified in 0.25  mL of WFI.  
• Group 5 : two doses ( days 1 and 22 ) of AGS -v PLUS ( 50 nmol each peptide) as a suspension in 
0.375  mL of saline and 0.125  mL of Alhydrogel®. 
 
All doses will be administered by [CONTACT_40719].  
  
The person administering the vaccine will be blinded to the type of formulation by [CONTACT_40720] . Trained and lic ensed study staff  will administer vaccine.  
  
Vaccine a dministration will be performed following these instructions as detailed in the CVD SOPs .  
  
Detailed instructions on how to administer a subcutaneous injection  can be found in CVD SOPs  and in 
the Pharmacy manual .  
 
5.5 Modification of Study Intervention/Investigational Product for a Participant  
The study product will be administered to enrolled participants according to the study schedule. There is 
no planned modification of study produ ct administration for participants.  
  
5.[ADDRESS_42365] Accountability  
The University of Maryland  Medical Center Investigational Drug Service  will be responsible for recording 
the receipt of all vaccine supplies and for ensuring the supervision of the storage and allocation of these 
supplies.  When a shipment is received, an assigned qualified person verifies the quantities received and 
the acco mpanying documentation and returns the acknowledgment of receipt to the drug supplier.  
  
Drug administration will be recorded in the source documents, in the e lectronic case report forms ( CRFs ) 
and in the Dr ug Administration Record form. The latter includ es the participant  identification, quantity 
(volum e) and date of administration. The containers from which the vaccine was administered to the 
participant s will be retained for dose confirmation.  
  
At the end of the study, delivery records of study vaccin e will be reconciled with used / unused stocks 
and appropriate forms will be completed, to verify that all used, unused or partially used supplies have 
been returned or destroyed and that no study supplies remain in the Investigator’s possession.  
  
 IND# [ZIP_CODE]  AGS -v PLUS  
Protocol, v 4.0 01 May  2020 AGS -v PLUS Mosquito Vax   
 
  
OCRPRO/DCR/NIAID/NIH  
CONFIDENTIAL  Page 34 of 67 All unused vaccine supplies, partially used and empty containers will be returned or destroyed after the 
study monitor has completed final accountability inspection and in agreement with the  drug supplier  
(SEEK) .  
 
5.6.[ADDRESS_42366] maintain IP 
accountability records throughout the course of the study. The investigator or designated site staff will 
document the amount of IP received from the drug supplier  (SEEK) and the amount administere d to 
participant s.  
A Drug Dispensing Log must be kept current and will contain the following information:   
• The identification of the participant  to whom the drug was dispensed.  
• The date(s) of the drug dispensed to the participant .  
  
The inventory must be available for inspection by [CONTACT_40721].  Drug 
supplies, excluding empty containers, will either be collected at the end of the study by [CONTACT_941] s tudy mo nitor,  
returned or destroyed by [CONTACT_40722] ( SEEK ). The PI [INVESTIGATOR_40636] r ecords indicating  identification and quantity of each unit disposed of  or returned , the method of 
destruction (taking into account  the requirements of local law), and the person who disposed of the test 
substance.  Such records must be submitted to the drug supplier.  
  
5.6.3 Retention of Samples  
It will be the responsibility of the drug supplier ( SEEK ) to ensure adequate samples of all study drug are 
retained in accordance with the regulatory guidelines.  
5.7  Concomitant Medications and Procedures  
At each study visit/contact  [CONTACT_40723] 366 the study team  will question the participant 
about any medication taken  starting from 30 days before screening , including herbals, vitamins and 
holistic/naturopathic medications. Concomitant medication, including vaccines and any other medication, 
will be recorded in th e CRF s with trade name [INVESTIGATOR_1238]/or generic name [CONTACT_11889], medical indication, 
start and end dates of treatment.   
 
[ADDRESS_42367] at the CVD, University of Maryland School of Medicine . All aspects of the 
protocol will be c arried out in accordance with CVD University of Maryland guidelines, Good Clinical 
Practice ( GCP ) and International Council for Harmonisation of Technical Requirements for 
Pharmaceuticals for Human Use  (ICH) involving human -participant research.  Please see  Figure 9 below.  
 
 IND# [ZIP_CODE]  AGS -v PLUS  
Protocol, v 4.0 01 May  2020 AGS -v PLUS Mosquito Vax   
 
  
OCRPRO/DCR/NIAID/NIH  
CONFIDENTIAL  Page 35 of 67                                 
 
Figure 9. Study schedule  
    
6.1 Screening (Days -60 to 0)  (outpatient visit)  
• Potential participant s will be provided with a verbal description of the study (purpose and study 
procedures), and will be asked if they have any questions and to read/sign the consent form. 
The consent form will be signed and potential participants must score >70% on a 
comprehension quiz before  the performance of any study procedures.  The comprehension quiz 
may be repeated once.  
• The study staff will discuss with the potential participant  his/her medical history, study eligibility 
criteri a and concomitant medication use.  
• Vital signs ( height, weight, oral  temperature, blood pressure, heart rate ) will be obtained. BMI 
will be calculated to ensure eligibility.  
• Documentation of usual responses to mosquito bites as none (0), mild (1), moderate (2), or 
severe (3) .  
• A physical exam will be performed.  
• For females who are capable of bearing children, a serum pregnancy test will be performed at 
the clinical trial study site at the time of screening regardless of age unless written medical 
demonstrati on of sterility or amenorrhea (defined as one year with medical evaluation)  can be 
provided.  
• A blood sample will be collected from an arm vein to screen for health as follows:  
o Hematology: hemoglobin (Hgb), white blood cell count (WBC), and platelet count ; 
o Chemistry: glucose (random), alanine aminotran sferase (ALT), and creatinine ; 
o Serology: HIV, hepatitis C virus ( HCV ), and hepatitis B surface antigen ( HBsAg ). 
• Medications taken in the previous 30 days will be recorded . 

 IND# [ZIP_CODE]  AGS -v PLUS  
Protocol, v 4.0 01 May  2020 AGS -v PLUS Mosquito Vax   
 
  
OCRPRO/DCR/NIAID/NIH  
CONFIDENTIAL  Page 36 of 67  
6.2  Enrollment/Baseline  and First Vaccination  (Day 1)  (outpatient visit)  
Randomization will use computer gene rated randomization codes. These  code s will be sent to the 
pharmacy where the unblinded pharmacist will have the key and prepare the appropr iate agent for 
administration. All vaccination syringes  will be labeled to cover contents  so that the blinded staff cannot  
identify the different treatments .    
 
The first vaccine or placebo administration will take place on Day 1. The research team will confirm 
continuing  consent with the volunteer before  performing any and all procedures. Once it is determined 
that the participant still meets inclusion/exclusion criteria for the research study, participants will receive 
the first of two injections.  
  
 The following procedures will be performed a t enrollm ent:  
• Review of medical/ concomi tant medication history  
• Targeted physical exam/assessment as needed   
• Vital signs pre -vaccination  
• Vital signs 30-[ADDRESS_42368] vaccination  
• Blood collection for routine safety labs ( Hemoglobin, white blood cell count, plate lets, serum 
creatinine, serum alanine aminotransferase, random glucose ) 
• serum/whole blood prevaccination for research (as per Appendix B ) 
• Urine  pregnancy test (females  of childbearing potential  only)  
• Review of inclusion/exclus ion criteria   
• Vaccine or placebo administration   
• Vaccine injection site and AE assessment pre -vaccination  and  
• 30-[ADDRESS_42369] vaccination  
• AE memory aid , thermometer, and ruler will be distributed before  discharge home  
 
6.3 Day 8 (+2 days)  (phone call) 
• Review of medical/medication history  
• Review of AEs and AE memory aid from first vaccination  
 
  
6.4 Day 2 2 (+/- 3 days) (outpatient visit)  
The second study vaccine administration will take place if the participant continues to meet all inclusio n 
and none of the exclusion criteria following these procedures:   
• Review of medical/medication history  
• Targeted physical  exam/assessment  as needed  
 IND# [ZIP_CODE]  AGS -v PLUS  
Protocol, v 4.0 01 May  2020 AGS -v PLUS Mosquito Vax   
 
  
OCRPRO/DCR/NIAID/NIH  
CONFIDENTIAL  Page 37 of 67 • Vital signs (temperature, heart rate, blood pressure)  
• Vital signs at least [ADDRESS_42370] vaccination  
• Blood collection for routine safety labs  (Hemoglobin, white blood cell count, platelets, serum 
creatinine, serum alanine aminotransferase, random glucose ) 
• Urine pregnancy test (females  of childbearing potential  only)  
• Vaccine or placebo administration   
• Vaccine injection site reaction and AE assessment pre -vaccination  and at least 30-[ADDRESS_42371] vaccination  
• AE memory aid , thermometer, and ruler will be distributed before  discharge home if the previous 
set is lost  
 
6.5 Day 29 (+2  days)  (phone call) 
• Review of medical/medication history  
• Review of AEs and AE memory aid from second vaccination  
• Participants will be asked not to apply cream, perfume or deodorant on the day of mosquito 
exposure.   
 
 
6.6  Day 4 3 Mosquito Feeding (+ 7 days) (outpatient visit)  
The following procedures/assessments and testing will be performed:  
• Review of medical/medication history and addition of any new information  
• Targeted p hysician assessment and physical exam if needed  
• Vital signs (temperature, heart rate, blood pressure)   
• Urine pregnancy test (females of reproductive potential only)  
• Blood collection for routine safety labs (hemoglobin, white blood cell count, platelets,  serum 
creatinine, serum alanine aminotransferase, random glu cose) 
• serum/whole blood for research before  mosquito feeding  as per Appendi x B.  
• Mosquito feeding: Starved clean female Aedes aegypti  and Aedes albopi[INVESTIGATOR_40637] a mosquito colony approved for human fee ding studies in Laboratory of Malaria 
and Vector Research (LMVR), NIAID.  Clean mosquitoes are referred to as mosquitoes colonized 
in an insectary and that are pathogen free.  Clean mosquitoes are raised in an incubator dedicated 
for clinical trials . This ensure s these insects are never exposed to human blood after emerge nce 
as adult mosquitoes up to the time they are utilized for feeding on human volunteers enrolled in 
the clinical trial. The insectary has well-established safety precautions to preven t outside 
mosquitoes from enter ing the facility. Mosquitoes will be aspi[INVESTIGATOR_38105] a secured Plexiglas 
feeding device and brought to the CVD from the LMVR Insectary.  
• There will be 1 0 participant s in each treatment arm. Each participant  will be exposed to 
Aedes aegypti  on the right  arm and Aedes albopi[INVESTIGATOR_40638].  
 IND# [ZIP_CODE]  AGS -v PLUS  
Protocol, v 4.0 01 May  2020 AGS -v PLUS Mosquito Vax   
 
  
OCRPRO/DCR/NIAID/NIH  
CONFIDENTIAL  Page 38 of 67 • The feeding site will be wiped clean with mild unscented soap and water and the device 
will be placed on the participant’s arm for 10-20 minutes. The mosquitos will feed throu gh 
a disposable mesh on the bottom of the feeding device. This device permits the 
evaluation of mosquito feeding on the human participant  at the end of exposure.  In the 
unlikely event of no feeding or poor feeding (only 0 -2 mosquitoes fed or probed as note d 
by [CONTACT_40724] a particular strain ), the volunteer may undergo a repeat feed with 5 -
10 fresh mosquitoes ONCE.   
• Participants will be asked not to apply cream, perfume or deodorant on the day of 
mosquito exposure.  Once the mosquitos have fed they will be brought back to the lab for 
further study.  
• The PI [INVESTIGATOR_40639] s at least 30 min after 
feeding.  
  
• AE assessment .  
 
6.7  Day 4 5 (+/- 1 day) (outpatient visit)  
Two days after t he mosquito feeding the participants will return for a follow -up. The following 
procedures/assessments and testing will be performed:  
• Review of medical/medication history and addition of any new information  
• Targeted physician assessment and physical exam  if needed  
• AE assessment  
• Mosquito bite assessment  
• Collection of 3 skin biopsies : [ADDRESS_42372] from an unbitten area of normal skin  
 
 6.8  Mosquito Feeding follow -up (Day 50 + 2 days ) 
Seven days after mosquito feeding, participant s will return for a follow -up. The following 
procedures/assessments and testing will be performed:  
• Review of medical/medication history and addition of any new information  
• Vital signs (temperature, heart rate , blood pressure)  
• Targeted p hysician assessment and physical exam if needed  
• Whole blood and s erum collection for research as per Appendix B  
• Blood collection for routine safety labs (Hemoglobin, white blood cell count, platelets , serum 
creatinine, serum alanine aminotransferase, random glucose ) 
• Mosquito bite assessment by [CONTACT_978] [INVESTIGATOR_40640]. 
• Assessment of biopsy healing  
• AE assessment   
 IND# [ZIP_CODE]  AGS -v PLUS  
Protocol, v 4.0 01 May  2020 AGS -v PLUS Mosquito Vax   
 
  
OCRPRO/DCR/NIAID/NIH  
CONFIDENTIAL  Page 39 of 67  
6.9  Telephone Safety Follow -up (Day 181 +14 days, and Day 366 +14 days )  
 
All participants will be followed for a minimum of [ADDRESS_42373] over a tele phone  call on days 181 and 366 (+/ - 14 days ). The study doctor 
will discuss ongoing , unresolved AEs with the participant and if deemed necessary , schedule a clinic visit. 
The procedures/evaluations to be conducted at these visits are shown in Appendix A . The follow -up call 
on day 366 will be the final study intervention unless the participant requires additional follow -up of study -
related complic ations.   
 IND# [ZIP_CODE]  AGS -v PLUS  
Protocol, v 4.0 01 May  2020 AGS -v PLUS Mosquito Vax   
 
  
OCRPRO/DCR/NIAID/NIH  
CONFIDENTIAL  Page 40 of 67 7  Study Procedures/ Evaluations  
 
7.1  Clinical and Laboratory Evaluations  
See Appendix A  for clinical and laboratory procedures performed during the vaccination and mosquito 
feeding visits as well as follow -up portions of the study. See Appendix B  for Blood Volumes for Specimen 
Collection. Many of these tests are being performed to monitor safety and ensure that participants are 
healthy enough to undergo vaccination and mosquito feeding. The CVD has established limits for blood 
draws for research purposes, and the planned blood draws are within these limits.  
7.1.1 Laboratory Testing of Collected Samples for Primary and Secondary Endpoints  
o AGS -v PLUS  specific IgG, IgM and IgE  assay will be performed using enzyme -linked 
immunosorbent assay (ELISA). The time points assayed will be day 1, day 43 and day 50. 
o Th1 and Th2  response assays: PBMCs collected from participants will be incubated with 
AGS -v PLUS and saliva from Aedes aegypti , Aedes albopi[INVESTIGATOR_40641]1 (Interferon -gamma)  and Th2 (Interleu kin-4) cytokines will be 
perfo rmed using ELISA. The time points assayed will be day 1, day 43 and day 50.  
o Biopsies taken on day 45 will be used to assess expression of inflammatory markers.  
o Feeding on human volunteers : [ADDRESS_42374] only been sugar -fed up until now. Female mosquitoes will be placed in a 
secured Plexiglass feeding device and allowed to feed on the volunteer’s arms on Day  43 
(approximately [ADDRESS_42375] completed the vaccination schedule). Each 
participant  from each arm will be exposed to the bites of Aedes aegypti  on the right arm 
and Aedes albopi[INVESTIGATOR_40642]. Mosquitoes that had a blood meal will then be 
removed and followed up to assess any changes to their life cycle, i.e., life -span, number 
of eggs laid, number of fertile eggs, number of surviving larvae et c. The mosquito colony 
used in this study will not be fed on human blood before exposure to participants, but on 
non-mammalian blood to minimize the presence of blood borne pathogens.  
o Zika virus killing, in vitro  toxicity assay:   
▪ Blood samples will be obt ained from all volunteers 21 days after vaccination is 
completed  (day 43 pre-feeding) . PBMCs+sera containing immune cells and antibodies 
generated against AGS -v PLUS  will be tested for their ability to kill or inactivate Zika 
virus coated with salivary gla nd proteins from Aedes aegypti  and Aedes albopi[INVESTIGATOR_40643] . 
Viability of the virus will be tested by [CONTACT_40725]/virus 
supernatants. Infectivity of the Zika virus will be assessed by [CONTACT_40726] . 
 
▪ Zika virus will be obtained from commercial supplier s and will be propagated in vitro .  
 
 IND# [ZIP_CODE]  AGS -v PLUS  
Protocol, v 4.0 01 May  2020 AGS -v PLUS Mosquito Vax   
 
  
OCRPRO/DCR/NIAID/NIH  
CONFIDENTIAL  Page [ADDRESS_42376] 
temperature, any local (redness, swelling, and pain) or general symptoms (e.g., fever, chills, headache, 
myalgia, arthralgia,  malaise,  sweats, fatigue, nausea, vomiting) they experience on the AE memory aid . 
At the day 8 and day 29 visits (phone cal l) the AE memory aid s will be reviewed via phone and study staff 
will record reactogenicity during their discussion with each participant .  
  
The AE memory aid  will be completed by [CONTACT_40727].  Participant s will be instructed on 
how to c omplete the card .  
 
7.3 Mosquito Bite Assessment   
 
Mosquito bites will be assessed by [CONTACT_978] [INVESTIGATOR_40644] 43 (30 minutes after mosquito 
feeding), 45, and 50. Local reaction will be assessed by [CONTACT_40728]/induration.  
  
[ADDRESS_42377] ion include pain, redness, 
swelling, edema, and purulent drainage at the site.  
8.2  Risks of AGS -v PLUS ± adjuvant vaccination  
Vaccine reactions must be considered a risk of all vaccines.  These include minor and severe vaccine 
reactions.  A minor vaccine reaction typi[INVESTIGATOR_40645] a few hours of injection and resolve within a 
short period of time posing little risk to the participant.  Symptoms include local pain, swelling, and redness 
at the site of injection and may include systemic symptoms like fe ver, malaise, muscle pain, headache, 
and loss of appetite.  Severe reactions usually do not result in long -term problems for the participant, but 
can be disabling.  They are rarely life threatening, but can be  in <0.5% of individuals . These reactions can 
include severe anaphylactic reactions and seizure.  Topi[INVESTIGATOR_40646], and topi[INVESTIGATOR_900] -pruritic and pain relief . 
Additional standard of care therapy for pain or an aphylaxis will be administered according to CVD 
standards if the reaction becomes severe or life threatening.   
  
The Sponsor has carried out a similar study testing the safety and immunogenicity of AGS -v, a vaccine 
that contains four of the five peptides in AGS -v PLUS  (NCT 03055000) . No safety concerns were raised 
by [CONTACT_40729].  
 
 IND# [ZIP_CODE]  AGS -v PLUS  
Protocol, v 4.0 01 May  2020 AGS -v PLUS Mosquito Vax   
 
  
OCRPRO/DCR/NIAID/NIH  
CONFIDENTIAL  Page [ADDRESS_42378] similar safety findings 
for AGS -v PLUS as were observed with FLU -v, HIV-v and AGS -v. Below is a brief safety summary for all 
trials above mentioned:  
 
• Phase 1 AGS -v 001: Safety issues had been mild in severity. The vaccinations were well tolerated. 
In the unadjuvan ted AGS -v group the most common AEs were Grade 1 or 2 injection site pain, 
fatigue, and headache (37.5%, 31.3%, 31.3% of participants respectively).  Some participants also 
experienced Grade 1 or 2 systemic reactions of myalgia/feverishness/chills/diaphores is (6.1 -
18.8% of participants).  The adjuvanted AGS -v group experienced a higher level of related AEs, 
with the most common being injection site pain, swelling, erythema, and pruritis (52.9%, 47.1%, 
41.2%, and 41.2% respectively).  They also experienced some  systemic grade1 and 2 AEs such 
as fatigue (41.2%) and feverishness (35.3%), as well as myalgia, chills and diaphoresis (5.9 -
29.4%). The placebo group experienced fewer AEs with only injection site pain and erythema in 
25% and 6.3% respectively.  They exper ienced a smaller amount of systemic AEs as well ranging 
from 6.3% to 12.5% for headache, fever, chills, fatigue, and myalgia. The most common AEs on 
Mosquito Feeding Day were Grade 1 erythema (93.8%) and Grade 1 local swelling (93.8 %).  
 
• Phase 1 FLU-v-001: no deaths occurred and only one SAE was reported with this being 
considered unrelated to FLU -v (appendicitis). There was no apparent increase in adverse events 
(AEs) with a change in dose from the 250 μg or 500 μg (500 ug of FLU -v is the equivalent of 825  
ug of AGS -v as both contain 50 nmol of each peptide and a total of four peptides), but an 
approximate two -fold increase in AEs was seen in the adjuvant versus non -adjuvant groups. This 
latter point is likely responsible for the largely local administratio n site reaction AEs, and the 
forearm site and 1 ml volume is suspected to be the cause rather than the adjuvant itself. In 
conclusion, no safety or tolerability concerns were identified.  
 
• Phase 1b FLU -v-002: all 32 participant s reported AEs: 32 mild, 10 mo derate and one severe (a 
pre-syncopal epi[INVESTIGATOR_40647]). There were no deaths or SAEs. The most frequently 
reported AEs were related to the injection site reactogenicity and are consistent with those already 
documented with use of the adjuvant.  There were no other clinically significant changes in the 
other safety parameters (complete physical examination, clinical chemistry, hematology and 
urinalysis, vital signs including oral temperature, electrocardiogram [ ECG ]). 
 
• Phase 2b FLU -v003: A total of 175 participant s were enrolled to take part in a study carried in the 
Netherlands as part of a large European Consortium (UNISEC). Participant s were allocated 
(2:2:1:1) to receive: 2 doses non -adjuvanted FLU -v, 1 dose of FLU -v adjuvanted in Montanide 
ISA-51, 2 doses of non -adjuvanted placebo or 1 dose adjuvanted placebo. The FLU -v vaccine 
formulations were safe and tolerated. A small number of participant s mainly in the adjuvanted 
FLU-v group experienced severe reactions at the injection site that resolv ed with the use of over 
the counter anti -inflammatory drugs and required no additional follow -up by [CONTACT_40730]. 
The majority of solicited AEs that were related to the vaccination were observed at the site of 
injection and those were mild to moderate in intensity. An increase in the number of adverse 
 IND# [ZIP_CODE]  AGS -v PLUS  
Protocol, v 4.0 01 May  2020 AGS -v PLUS Mosquito Vax   
 
  
OCRPRO/DCR/NIAID/NIH  
CONFIDENTIAL  Page [ADDRESS_42379] a tendency to create indurations at the site 
of injecti on which slowly disappear as the antigen is processed and the water in oil emulsion is 
degraded. Adjuvanted placebo had considerable more treatment emergent adverse events 
(TEAEs ) definitely related to treatment than non -adjuvanted placebo (74.1% vs 18.8% 
participant s). Addition of FLU -v to the placebo formulations increased the number of participant s 
experiencing TEAEs (74.1 % to 93% of participant s in adjuvanted placebo to adjuva nted FLU -v, 
and 18.8% to 34.5% participant s in non -adjuvanted placebo to non -adjuvanted FLU -v). This 
indicates that the antigen itself is immunogenic and induces a small inflammatory reaction that 
translates into AEs at the injection site. These AEs were m ostly mild to moderate with the 
participant s in adjuvanted FLU -v group showing the highest number of these AEs. A total of 20 
participant s experienced adverse events classified as severe in intensity with only 7 of them being 
definitely related to the stud y drug and defined as reactions at the site of the injection (1/58 in 
non-adjuvanted FLU -v, 5/57 in adjuvanted FLU -v, 0/32 in non -adjuvanted placebo and 1/27 in 
adjuvanted placebo).  
 
• Phase 2b FLU -v004: 121 participant s were randomized (1:1:1) into one of three arms: 2 doses 
adjuvanted placebo (Montanide ISA -51+WFI), two doses adjuvanted FLU -v or one dose 
adjuvanted FLU -v +adjuvanted placebo. Participant s were then challenged with an H1N1 
influenza virus. Overall the data showed a good safety profile for th e IMP. The single dose FLU -
v showed a better profile than the 2 doses.  However, there were no significant issues with the 
single dose arm and no concerns with the 2 -dose arm.  Injection site reactions were as expected 
and of an ‘acceptable’ level.  A greater  incidence of local reactions was seen in active arms, which 
may suggest a local reaction to the protein in addition to the adjuvant. The number of definitely 
related AEs in both FLU -v treatment groups was considerably higher than the placebo but of 
simila r severity. The main AE was induration at the site of the injection and was considerably 
higher in the vaccine groups than placebo (46.8% and 60.8% compared to 18%).  
 
• Phase 1b HIV -v-001: all [ADDRESS_42380] commonly reported AEs. The majority of AEs were of mild severity (69.7%).  There were 
[ADDRESS_42381] trials  were related to ca ncer 
and Acquired Immune Deficiency Syndrome (AIDS). Currently,  cancer trials in melanoma, colorectal, 
prostate, cervical, brain cancer and leukemia  are ongoing. Frequency of vaccination is often between [ADDRESS_42382] common local  reactions are local pain, 
tenderness, erythema and granuloma at the injection site.  Less frequently, mild to moderate transient 
indurations and swelling are described.  General reactions are mainly ‘flu -like symptoms such as chills, 
 IND# [ZIP_CODE]  AGS -v PLUS  
Protocol, v 4.0 01 May  2020 AGS -v PLUS Mosquito Vax   
 
  
OCRPRO/DCR/NIAID/NIH  
CONFIDENTIAL  Page 44 of 67 fever and headaches.  Lethargy and nausea are also observed. The intensity is usually mild or moderate. 
No biological ch anges are generally observed .  
 
Aluminium based adjuvants  
Alhydrogel® has been used in many commercial vaccines29. After almost a century, aluminum salts 
maintain their dominance as adjuvants in human vaccines. This reflects the fact that aluminu m adjuvants 
are extremely effective at enhancing antibody responses, are well tolerated, do not cause pyrexia and 
have the strongest safety record of any human adjuvants . Hence, aluminum adjuvants remain the gold 
standard against which all new adjuvants ne ed to be compared and any new adjuvant must prove it 
provides better protection, tolerability or safety, or preferably all, when compared to aluminum adjuvant. 
Aluminum adjuvants suffer from a number of minor toxicities potentially explained by [CONTACT_40731]. For example, aluminum induces injectio n site pain and tenderness that may reflect cell necrosis 
and induction of inflammasome activation and IL1 production  which explains why some participant s 
develop persistent lumps and g ranulomas at the i njection site . Aluminum adjuvants may also induce 
contact [CONTACT_40732] a fraction of im munized participant s. Aluminum adjuvant -containing 
vaccines can cause post -immunization headache, arthralgia and myalgia, which could reflect alum’s 
propens ity to induce IL -1, with IL1 administration to human participant s reproducing these symptoms . On 
the positive side, aluminum adjuvants rarely cause severe local reactions and are not normally 
associated with systemic inflammatory problems such as pyrexia29. 
 
 
8.4  Risks of blood draw  
Risks of blood draw include pain, bruising, bleeding, and rarely fainting or infection.  To minimize this risk, 
the skin is cleaned with alcohol before puncture; sterile, unused needles  and lancets will always be used; 
and pressure will be held at the puncture site after removal of the needle or lancet. Although the quantity 
of blood drawn would not lead to any ill effects on the participants’ health, some adults feel faint with 
phleboto my. This risk will be minimized by [CONTACT_40733], and by 
[CONTACT_40734] a recumbent position if they feel light headed or appear as if they are about to faint. 
Clinicians will be available for evaluation if there  is any untoward effect.  
 
8.5  Risks of Aedes aegypti  and Aedes albopi[INVESTIGATOR_40648], but participants may suffer pruritis, mild rash, or irritation at the 
site of the bites.  This may require topi[INVESTIGATOR_40649].  In rare cases a more severe irritation 
could occur, anaphylactic reaction, or secondary infection at the site of the bite where antibiotics or 
systemic anti -inflammatory medication may be required.  
8.6 Risk of Skin Biopsies  
From each participant, three 3 mm skin biopsies will be taken, one from the A.  aegypti bite (right arm), 
one from the A. albopi[INVESTIGATOR_40650] (left arm) and the last one from  normal unbitten skin (control).  Risks of 
biopsy include local pain, bleeding, redness, infection , a scar and possible keloid formation. Oral or 
topi[INVESTIGATOR_40651]. Any non -
routine complications resulting from the procedure will be addressed in consultation with the NIH 
 IND# [ZIP_CODE]  AGS -v PLUS  
Protocol, v 4.0 01 May  2020 AGS -v PLUS Mosquito Vax   
 
  
OCRPRO/DCR/NIAID/NIH  
CONFIDENTIAL  Page 45 of 67 Clinical Center ( CC) Dermatology service. Injection of local anesthetic may cause a minimal burning 
discomfort or bruising at the site of the needle puncture.  
 
8.[ADDRESS_42383] benefit to the partic ipant.  The information 
collected from this study will allow a better understanding of the safety and immunogenicity of AGS -v 
PLUS and may inform further development of this or other universal mosquito -borne disease vaccines.  
 
9  Research Use of Stored Hum an Samples, Specimens, or Data  
 
Intended Use: Samples and data collected under this protocol may be used to study aspects of Zika 
virus infection and other mosquito -borne diseases. Genetic testing will not be performed. A separate 
signed informed consent document will be obtained for any other research not described in this protocol.  
Storage: Access to stored samples will be limited using a locked freezer in a locked laboratory. Samples 
and data will be stored using codes assigned by [CONTACT_473]. Da ta will be kept in password -protected 
computers  or in locked cabinets in locked rooms accessed only by [CONTACT_464] . Only investigators and 
designated study staff will have access to the samples and data.   
Tracking: Samples will initially be stored in labor atories of primary and associate investigators. Samples 
will be tracked using a database located on password -protected computers, which will be maintained by 
[CONTACT_40735]. Only investigators and their designees will have access to this 
database.   
Disposition at the Completion of the Protocol:   
• In the future, other investigators may wish to study these samples and/or data. In that case, IRB 
approval must be sought before  any sharing of samples and/or data. Any clinical information shared 
about the samples would similarly require prior IRB approva l.  
• At the completion of the protocol (termination), samples will be stored at suitable conditions for a 
minimum of 1 year. After this time and in agreement between the Sponsor and vaccine manufacturer, 
SEEK, the samples will either be destroyed, or after IRB approval, transferred to another existing 
protocol.  
• At the completion of the protocol (termination), data will be stored for a minimum of 3  years. After 
this time and in agreement between the Sponsor and vaccine manufa cturer, SEEK, the data will 
either be destroyed, or after IRB approval, transferred to another existing protocol.  
 
Reporting Loss or Destruction of Samples/Specimens/Data to the IRB:  
• Any loss or unanticipated destruction of samples or data (for example, due to freezer malfunction) 
that meets the definition of protocol deviation and/or compromises the scientific integrity of the data 
 IND# [ZIP_CODE]  AGS -v PLUS  
Protocol, v 4.0 01 May  2020 AGS -v PLUS Mosquito Vax   
 
  
OCRPRO/DCR/NIAID/NIH  
CONFIDENTIAL  Page 46 of 67 collected for the study will be reported to the IRB  in accordance with local regulations . The PI [INVESTIGATOR_40652].  
• Additionally, participant s may decide at any point not to have their samples stored. In this case, the 
PI [INVESTIGATOR_40653]. This decision will not affect the subject’s participation in this protocol or any other protocols 
at CVD .  
10  Data Sharing Plan  
 
10.1  Sharing of Human Data  
Human data generated in this study will be shared for future research as follows:  
• De-identified data in an NIH -funded or approved public repository.  
• Identified data in Biomedical Translational Research Information System ( BTRIS ).  
• De-identified or identified data with approved outside collaborators under appropriate 
agreements.  
Data w ill be shared through :  
• ClinicalTrials.gov  
• BTRIS.  
• Approved outside collaborators under appropriate individual agreements.  
• Publication and/or public presentations  at scientific meetings .  
 
[ADDRESS_42384] with the participant, information regarding AEs will be elicited by [CONTACT_40736]:   
• Immediately documented in the participant’s medical record/source document,  
• Recorded in the study database  
• Reported as outlined below (e.g., Investigational New Drug ( IND) Sponsor, IRB, FDA).   
 IND# [ZIP_CODE]  AGS -v PLUS  
Protocol, v 4.0 01 May  2020 AGS -v PLUS Mosquito Vax   
 
  
OCRPRO/DCR/NIAID/NIH  
CONFIDENTIAL  Page 47 of 67 If a diagnosis is clinically evident (or subsequently determi ned), the diagnosis rather than the individual 
signs and symptoms or lab abnormalities will be recorded as the AE.  
  
All abnormal laboratory findings will be reviewed on a routine basis by [CONTACT_978] [INVESTIGATOR_40654]. An abnorm al lab not included on the toxicity table should be assessed in a similar 
fashion to the criteria above.  
 
12.2  Definitions  
  
Adverse Event  (AE) 
An AE is any untoward or unfavorable medical occurrence in a human subject, including any abnormal 
sign (for example, abnormal physical exam, or laboratory finding), symptom, or disease, temporally 
associated with the subject’s participation in the researc h, whether or not considered related to the 
research.   
 
Treatment Emergent Adverse Event (TEAE)  
A TEAE is any untoward or unfavorable medical occurrence in a human subject, including any abnormal 
sign (for example, abnormal physical exam, or laboratory fin ding), symptom, or disease, that manifested 
after administration of the study treatment , whether or not considered related to the treatment . 
  
Adverse Reaction (AR)  
An AE that is caused by [CONTACT_4523] (drug or biologic).  
  
Protocol Deviation  
A protocol deviation is any noncompliance with the clinical trial protocol, Good Clinical Practice (GCP), 
or Manual of Procedures requirements. The noncompliance may be either on the part of the subject, 
the investigator, or the study site staff.  As a result of deviations, corrective actions are to be developed 
by [CONTACT_40737].  
These practices are consistent with ICH E6:  
  4.5 Compliance with Protocol, Sec tions 4.5.1, 4.5.2, and 4.5.3  
  5.1 Quality Assurance and Quality Cont rol, Section 5.1.1  
  5.2.0  Noncompliance, Sections 5.20.1, and 5.20.2.  
 
Suspected AR (SAR)  
An AE for which there is a reasonable possibility that the investigational agent caused the AE. 
‘Reasonable possibility’ means that there is evidence to suggest a c ausal relationship between the drug 
and the AE. A SAR implies a lesser degree of certainty about causality than AR, which implies a high 
degree of certainty.  
  
Serious Adverse Event (SAE)  
An SAE is an AE that results in 1 or more of the following outcome s:  
• Death  
 IND# [ZIP_CODE]  AGS -v PLUS  
Protocol, v 4.0 01 May  2020 AGS -v PLUS Mosquito Vax   
 
  
OCRPRO/DCR/NIAID/NIH  
CONFIDENTIAL  Page 48 of 67 • A life -threatening event (places the subject at immediate risk of death from the event as it 
occurred)  
• An inpatient hospi[INVESTIGATOR_1324]  
• A persistent or significant incapacity or substantial disruption of the ability to conduct normal 
life functions   
• A congenital anomaly/birth defect  
• A medically important event*  
*Medical and scientific judgment should be exercised in deciding whether expedited reporting is 
appropriate in other situations, su ch as important medical events that may not be immediately life 
threatening or result in death or hospi[INVESTIGATOR_40655].  
  
Unexpected Adverse Event  (UAE)  
An AE is unexpected if it is not listed in the Investigator’s  Brochure or Package Insert (for marketed 
products) or is not listed at the specificity or severity that has been observed. It is the responsibility of the 
IND sponsor to make this determin ation.  
  
Serious and Unexpected SAR (S[LOCATION_003]R)  
A S[LOCATION_003]R is a SAR that is both serious and unexpected.  
  
Unanticipated Problem (UP)  
A UP is any event, incident, experience, or outcome that is  
1. Unexpected in terms of nature, severity, or frequency in relation to  
a. The research risks that are described in the IRB -approved research protocol and informed 
consent document, Investigator’s Brochure, or other study documents; and  
b. The characteristics of the participant population being studied; and  
2. Possibly, probably, or definitely related to participation in the research; and  
3. Places participants or others at a greater risk of harm (including physical, psychological, 
economic, or social harm) than was p reviously known or recognized. (Per the IND Sponsor, an 
AE with a serious outcome will be considered increased risk) .  
  
Serious Unanticipated Problem  
A UP that  meets the definition of a Serious Adverse Event or compromises the safety, welfare or rights 
of subjects or others.  
 
UP that is not an AE (UPnonAE )  
An UP that does not fit the definition of an AE, but which may, in the opi[INVESTIGATOR_871], involve 
risk to the subject, affect others in the research study, or significantly impact the integrit y of research 
data. Such events would be considered a non -serious UP. For example, breaches of confidentiality, 
accidental destruction of study records, or unaccounted -for study agent will be reported.  
  
 IND# [ZIP_CODE]  AGS -v PLUS  
Protocol, v 4.0 01 May  2020 AGS -v PLUS Mosquito Vax   
 
  
OCRPRO/DCR/NIAID/NIH  
CONFIDENTIAL  Page [ADDRESS_42385] to seriousness (criteria listed above), severity (intensity 
or grade), and causality (relationship to study agent and relationship to research) according to the 
following guidelines.   
  
12.3.1 Severity  
The inv estigator will grade the severity of each AE according to Appendix C . For items not found in 
Appendix C , the investigator will use the FDA “Toxicity Grading Scale for Healthy Adult and Adolescent 
Volunteers Enrolled in Preventive Vaccine Clinical Trials” September 2007, which can be found at:  . 
https://www.fda.gov/regulatory -information/search -fda-guidance -documents/toxicity -grading -scale -
healthy -adult-and-adolescent -volunteers -enrolled -preventive -vaccine -clinical  
 
  
All lab and vital sign abnormalities found before  administration of the vaccine or placebo will be 
documented as a baseline AE and will be assessed for clinical significa nce and the participant will be 
reassessed for inclusion or exclusion to receive vaccination.  After administration of vaccine or placebo, 
all new gradable abnormalities not found at baseline will be reported as AEs.   
  
Severity grading for clinical events that are not found in the FDA Healthy Volunteer Toxicity Table will be 
graded according to the following grading scale:  
  
• Grade 1 (Mild)   
Events causing no or minimal interference with daily activity and not requiring medical 
intervention  
• Grade 2 (Moderate)  
  Events causing greater than minimal interference with daily activity but not requiring medical 
intervention  
• Grade 3 (Severe)  
  Events causing inability to perform daily activity and/or requiring medical intervention  
• Grade 4 (Potent ially Life -Threatening)*  
  Events causing inability to perform basic self -care functions OR medical or operative 
intervention indicated to prevent permanent impairment, persistent disability, or death  
• Grade 5 (Death)  
Events causing death  
 
  
*Note:  A sever ity assessment of “potentially life -threatening” is not necessarily the same as life -
threatening as an "SAE" criterion. The latter means that the event is an immediate threat to life as 
opposed to a potential threat to life.  
 IND# [ZIP_CODE]  AGS -v PLUS  
Protocol, v 4.0 01 May  2020 AGS -v PLUS Mosquito Vax   
 
  
OCRPRO/DCR/NIAID/NIH  
CONFIDENTIAL  Page 50 of 67 12.3.2 Causality  
Causality (likelihood that the event is caused by [CONTACT_4526]) will be assessed considering the factors 
listed under the following categories:  
  
Definitely Related  
• Reasonable temporal relationship  
• Follows a known response pattern  
• Clear evidence to suggest a causal relationship  
• There is no alternative etiology  
  
Probably Related  
• Reasonable temporal relationship  
• Follows a suspected response pattern (based on similar products)  
• No evidence of a more likely alternative etiology  
  
Possibly Related  
• Reasonable temporal relationship  
• Little evidence for a more likely alternative etiology  
  
Unlikely Related  
• Does not have a reasonable temporal relationship   
OR  
• Good evidence for a m ore likely alternative etiology  
  
Not Related  
• Does not have a temporal relationship   
OR  
• Definitely due to an alternative etiology  
  
Note: Other factors should also be considered for each causality category when appropriate. Causality 
assessment is based on available information at the time of the assessment of the AE. The investigator 
may revise the causality assessment as additional i nformation becomes available.  
 
12.4  Investigator Reporting Responsibilities to the Sponsor   
12.4.1 AEs  
AE data will be submitted to the IND sponsor when requested for periodic safety assessments, review of 
IND annual reports, review of IND safety report s, and preparation of final study reports.  
 IND# [ZIP_CODE]  AGS -v PLUS  
Protocol, v 4.0 01 May  2020 AGS -v PLUS Mosquito Vax   
 
  
OCRPRO/DCR/NIAID/NIH  
CONFIDENTIAL  Page 51 of 67 12.4.2 SAEs  
All SAEs (regardless of relationship and whether or not they are also UPs) must be reported on the Safety 
Expedited Report Form (SERF)  or Red Cap system  and sent to the Sponsor Clinical Safety Office  (CSO) 
by [CONTACT_3719] e -mail attachment , or directly online  via secure server . Deaths and immediately life  threatening 
SAEs will be reported within [ADDRESS_42386] INFORMATION:   
Clinical Safety Office  
[ADDRESS_42387]  
Frederick, MD [ZIP_CODE]  
Phone: 301 -846-5301  
Fax: 301 -846-6224  
E-mail: [EMAIL_007]    
12.4.[ADDRESS_42388] be reported to the CSO and sent by [CONTACT_3719] e -mail attachment using the NIH 
Problem Report Form no later than 7 calendar days of site awareness of the event. Report Ups that are 
also AEs to the CSO on a SERF or a local IRB UP form.  UPs that are not AEs are not reported to the 
Sponsor CSO.  
12.4.4 Pregnancy   
All pregnancies will be reported on the Pregnancy Notification/Outcome Form to the CSO within 1 
business day from site awareness.  
  
Pregnancy outcome data (e.g., delivery outcom e, spontaneous or elective termination of the pregnancy) 
will be reported to the CSO within 3 business days of the site’s awareness.  
 Although pregnancy itself is not an AE, events that meet SAE criteria during pregnancy, delivery, or in 
the neonate (e.g. , congenital anomaly/birth defect) are reportable on the SERF.  
  
In the event of pregnancy, the following steps will be taken:  
• Discontinue the study agent and procedures but continue to follow -up for safety.  
• Report to the Data and Safety Monitoring Board (DSMB) and the IRB.  
• Advise the research participant  to notify the obstetrician of study participation and study agent 
exposure .  
12.5  Investigator Reporting Responsibilities to the University of Maryland, Baltimore ( UMB ) 
IRB  
12.5. [ADDRESS_42389] 
be promptly reported to the sponsor  per the sponsor’s  protocol deviation reporting procedures.  
 IND# [ZIP_CODE]  AGS -v PLUS  
Protocol, v 4.0 01 May  2020 AGS -v PLUS Mosquito Vax   
 
  
OCRPRO/DCR/NIAID/NIH  
CONFIDENTIAL  Page [ADDRESS_42390]'s chart  
for subject -specific protocol deviations . Protocol deviations must be sent to the UMB  IRB per their 
guidelines. The site pri ncipal investigator and personnel are responsible for knowing and adhering to 
their IRB requirements.  
 
12.5. [ADDRESS_42391] that may require expedited reporting  to the UMB IRB  (as per UMB IRB 
reporting guide lines in Appendix D) and/or safety evaluation include, but are not limited to:  
• Overdose of a study drug  
• Suspected abuse/misuse of a study drug  
• Inadvertent or accidental exposure to a study drug  
• Medication error involving a product (with or without participant /patient exposure to the study 
drug, e.g., name [CONTACT_2976])  
  
All protocol deviations  should be rec orded  in the study database .  
12.5. [ADDRESS_42392] 
not resolved by [CONTACT_40738] -up period will be recorded as “ongoing.” Any participant who 
experiences complications due to vaccine/placebo administration will be followed until resolution of such 
complication s or appropriate referral to the necessary medical care has been made.  
  
SAEs that have not resolved by [CONTACT_1008] -up period will be followed until final outcome  is 
known. If it is not possible to obtain a final outcome for an SAE (e.g., the participant is lost to  follow -up), 
 IND# [ZIP_CODE]  AGS -v PLUS  
Protocol, v 4.0 01 May  2020 AGS -v PLUS Mosquito Vax   
 
  
OCRPRO/DCR/NIAID/NIH  
CONFIDENTIAL  Page 53 of 67 the reason a final outcome could not be obtained will be recorded by [CONTACT_40739].   
  
SAEs that oc cur after the Day 366 phone call that are reported to and are assessed by [CONTACT_40740], probably, or definitely related will be reported to the CSO, as described above (section 
12.4.2 SAEs ).  
12.7  Sponsor’s Reporting Responsibilities  
S[LOCATION_003]Rs as defined in 21 CFR 312.32 and determined by [CONTACT_40741].   
  
The IND Sponsor will also submit an IND Annual Report of the progress of the investigation to the FDA 
as defined in 21 CFR 312.33.   
12.8  Pausing Rules for an Individual Participant   
Pausing is the suspension of administration of study agent to a single participan t until a decision is made 
whether or not to resume administration of the study agent.  
  
The pausing criteria for a single participant  in this study include any of the following:  
• A participant  experiences an SAE that is possibly, probably, or definitely related to a study 
agent;  
• A participant  experiences two Grade 3 or greater AEs that are possibly, probably, or definitely 
related to a study agent;  
• Any safety issue that the site investigator determine s should pause administration of a study 
agent to a single participant .  
  
The CSO, in collaboration with the PI, may also pause for an entire group if a safety concern is identified.  
12.8.1 Reporting a Pause  
If a pausing criterion is met, a description of the AE(s) or  safety issue must be reported by [CONTACT_978] [INVESTIGATOR_40656] 1 business day  of recognition of the event  to the CSO, the IRB, and the DSMB by [CONTACT_40742].  
12.8.2 Resumption of a Paused Study  
The CSO, in collaboration with the PI [INVESTIGATOR_40657] , will determi ne whether or not it is safe to resume 
administration of the study agent to the participant . The PI [INVESTIGATOR_40658].  
  
A participant  who does not resume study agent will continue to be followed for safety.  
  
 IND# [ZIP_CODE]  AGS -v PLUS  
Protocol, v 4.0 01 May  2020 AGS -v PLUS Mosquito Vax   
 
  
OCRPRO/DCR/NIAID/NIH  
CONFIDENTIAL  Page 54 of 67 12.9  Halting Rules for the Protocol  
Halting the study requires immediate discontinuation of study agent administered for all participant s and 
suspension of enrollment until a de cision is made whether or not to continue enrollment and study agent 
administration.  
  
The halting rules are:  
• 1 or more participant s experience the same or similar SAEs that are possibly, probably, or 
definitely related to the study agent;  
OR  
• 2 or more of the same or similar AE in different participant s that are grade 3 or above and are 
possibly, probably, or definitely related to t he study agent;  
OR  
• Any safety issue that the PI [INVESTIGATOR_1238]/or the CSO determines should halt the study.  
  
The PI [INVESTIGATOR_1238]/or CSO will determine if the study should be halted. In addition, the FDA may halt the study 
at any time following review of any safety concern s.  
  
12.9.1 Reporting a Study Halt  
If a halting rule is met, a description of the AE(s) or safety issue must be reported by [CONTACT_978] [INVESTIGATOR_40659] 1  business day to the Co-Investigator, IND Sponsor, CSO, the IRB, and the DSMB by [CONTACT_40743].  
12.9.2 Resumption of a Halted Study  
The IND sponsor, in collaboration with the PI [INVESTIGATOR_40660]. The PI [INVESTIGATOR_40661].  
  
Participant s who do not resume study agent will continue to be followed for safety.  
 
  
12.10 Study Discontinuation  
Office of Clinical Research Policy and Regulatory Operations ( OCRPRO ), the study sponsor, the IRB, 
and the FDA have the right to terminate this study at any time.  Reasons for terminating the study may 
include, but are not limited to, the following:  
1. The incidence or severity of AEs in this study indicates a potential health hazard to participants  
2. Participant enrollment is unsatisfactory  
3. Data recording  is inaccurate or incomplete  
4. Investigators do not adhere to the protocol, or applicable regulatory guidelines in conducting 
the study  
  
The IRB, the NIAID, the FDA, or other government agencies, as part of their duties to ensure that research 
participants are protected may discontinue the study at any time. Subsequent review of serious, 
unexpected and related AEs by [CONTACT_1201], the DSMB , the sponsor, the FDA, and other regulatory 
 IND# [ZIP_CODE]  AGS -v PLUS  
Protocol, v 4.0 01 May  2020 AGS -v PLUS Mosquito Vax   
 
  
OCRPRO/DCR/NIAID/NIH  
CONFIDENTIAL  Page 55 of 67 authorities may also result in suspension of further trial interventions/administration of study agent at a 
site. The FDA, other regulatory authorities, and the study sponsor retain the authority to suspend 
additional  enrollment and study agent administration for the entire study as applicable.  
   
12.11 Premature Withdrawal of a Participant  
Participants may withdraw before  vaccine administration and no further testing or follow -up will be 
performed. The PI [INVESTIGATOR_40662]/he wants to prematurely  withdraw 
from the study to determine the best course of action for the participant. If the participant would like to 
withdraw after vaccination, clinical laboratory tests and procedures for  safety purposes will continue as 
obtainable and at a frequency determined by [CONTACT_978]. If the participant does not return for scheduled follow -
up visits, the study staff will make every reasonable effort to contact [CONTACT_40744], mail, or 
email, or a combination of the latter and reiterate that follow -up visits are strongly encouraged for safety 
reasons.    
  
An individual participant  will be withdrawn for any of the following:  
• An individual participant ’s decision. (The investigator should attempt  to determine the reason for 
the participant ’s decision.)  
• Non-compliance with study procedures to the extent that it is potentially harmful to the participant  
or to the integrity of the study data.  
• A change in the participant ’s baseline condition after e nrollment so that the participant  no longer 
meets one or more of the inclusion/exclusion criteria.  
• The investigator determines that continued participation in the study would not be in the best 
interest of the participant .  
 
12.12  Replacement of a Partici pant  
If a participant withdraws or appears ineligible to continue the study before vaccine/placebo 
administration, he/she will be removed  and no data will be used in analysis or publication of the study. 
The participant may be replaced in the accrual with a new volunteer who qualifies and consents to the 
study , and who can complete both vaccinations [ADDRESS_42393] withdrawn will be used and included in the safety 
analysis.  
12.13 Safety Oversight  
12.13.1 Safety Review and Communications Plan (SRCP)  
A Safety Review and Communication Plan (S RCP) has been developed for the protocol. The SRCP is 
an internal communications document between the PI [INVESTIGATOR_40663], which delineates the safety oversight 
responsibilities of the PI, the CSO, and other stakeholders. The SRCP also includes the overall plan for 
cond ucting periodic safety surveillance assessments.   
 IND# [ZIP_CODE]  AGS -v PLUS  
Protocol, v 4.0 01 May  2020 AGS -v PLUS Mosquito Vax   
 
  
OCRPRO/DCR/NIAID/NIH  
CONFIDENTIAL  Page 56 of 67 12.13.2 Sponsor Medical Monitor  
A Medical Monitor, representing the IND Sponsor (OCRPRO), has been appointed for oversight of safety 
in this clinical study. The Sponsor Medical Monitor will be responsible for performing routine safety 
assessments in an SRCP.  
12.13.[ADDRESS_42394] (DSMB) includes independent experts that do 
not have direct involvement in the conduct of the study and h ave no significant conflicts of interest as 
defined by [CONTACT_40745]. The DSMB will review the study protocol, consent document(s), and 
investigator brochure prior to initiation and twice a year thereafter, or as may be determined by [CONTACT_40746].  
   
The DSMB m ay convene additional reviews as necessary. The DSMB will review the study data as 
needed to evaluate the safety, efficacy, study progress, and conduct of the study.   
  
All deaths, SAEs, UPs, pregnancies, and IND safety reports will be reported to the DSMB  at the 
same time they are submitted to the IRB and CSO unless otherwise specified herein.  
  
All cases of intentional or unintentional unblinding will be reported to the DSMB not later than one 
business day from the time of study personnel awareness.   
  
The principal investigator [INVESTIGATOR_40664] a recommendation concerning continuation, modification, or termination of the study. The 
principal investigator [INVESTIGATOR_40665] r eports with recommendations to the 
IRB(s).  
 
13  Site Monitoring Plan  
According to the ICH -GCP 5.18 and FDA 21 CFR 312.50, clinical protocols are required to be adequately 
monitored by [CONTACT_4530]. This study monitoring will be conducted according to the sponsor’s  
clinical monitoring guidelines . Clinical m onitors will visit the clinical re search site to monitor aspects of 
the study in accordance with the appropriate regulations and the approved protocol. The objectives of a 
monitoring visit will be:  
1) To verify the existence of signed informed consent documents and documentation of the in formed 
consent process for each monitored participant;  
2) To verify the prompt and accurate recording of all monitored data points, and prompt reporting of all 
SAEs;  
3) To compare clinical data abstracts with individual participants’ records and source documents 
(participants’ charts, laboratory analyses and test results, physicians’ progress notes, nurses’ notes, and 
any other relevant original participant information); and   
4) To help ensure investigators are in compliance with the protocol. The monitors also will inspect the 
clinical site regulatory files to ensure that regulatory requirements (FDA ; University of Maryland, 
Baltimore ; Office for Human Research Protections [ OHRP]) and applicable guidelines (ICH -GCP) are 
being followed. During the monitoring visits, the investigator (and/or designee) and other study personnel 
will be available to discuss the study progress and monitoring visit.  
 IND# [ZIP_CODE]  AGS -v PLUS  
Protocol, v 4.0 01 May  2020 AGS -v PLUS Mosquito Vax   
 
  
OCRPRO/DCR/NIAID/NIH  
CONFIDENTIAL  Page 57 of 67 The investigator (and/or design ee) will make study documents (e.g., consent forms, clinical data 
abstracts, and pertinent hospi[INVESTIGATOR_893]) readily available for inspection by [CONTACT_1622], IRB, site 
monitors, and NIAID staff for confirmation of the study data.   
  
A specific prot ocol monitoring plan will be discussed with the PI [INVESTIGATOR_40666]. The 
plan will outline the frequency of monitoring visits based on such factors as study enrollment, data 
collection status, and regulatory obligations.   
 
14  Statistical Considerations   
 
14.1  Study Hypothesis  
The study hypothesis is that : 
- AGS -v PLUS specific immunoglobulin will increase after vaccination with AGS -v PLUS  compared to 
placebo  
-PBMCs collected after vaccination with AGS -v PLUS incubated with AGS -v PLUS antigens will show a 
greater Th1 response as compared to placebo vaccination. Interferon –gamma is the main cytokine 
marker for Th1 responses.  
14.[ADDRESS_42395] one SAE 
that is possibly, probably or definitely related to vaccine  (halting rule 1) . With [ADDRESS_42396] an 80% chance of observing at least one participant with at least one S AE if the 
true underlying rate for that SAE in a vaccinated arm is 0.[ADDRESS_42397] a 10% chance of observing at 
least one SAE if the true underlying rat e is .01. If we collapse across the vaccinated arms we would have 
[ADDRESS_42398] a 9 5% chance  of observing at least one participant 
with AEs if the true rate is 0. 07. There is a 4% chance of observing at least one SAE o ut of [ADDRESS_42399] 2 or more of the same or similar AE’s (possibly, probably  
or definitely related to vaccine) that are grade [ADDRESS_42400] an 80% chance of obser ving [ADDRESS_42401] a less than a 1% chance of observing at least 
[ADDRESS_42402] an 84% chance of observing at least two participants  
with AEs if the true rate is 0.08. There is a 6% chance  of observing at least two AE out of [ADDRESS_42403] one participant with an S AE 
for various true SAE rates with samples sizes of 10 and 40.  
 IND# [ZIP_CODE]  AGS -v PLUS  
Protocol, v 4.0 01 May  2020 AGS -v PLUS Mosquito Vax   
 
  
OCRPRO/DCR/NIAID/NIH  
CONFIDENTIAL  Page 58 of 67  
Since this is a Phase 1b study we are looking for activity of the vaccine that would indicate the vaccines 
should be studied further. Since we do not wish to expose more participants than nece ssary to an 
experimental vaccine but we also don’t wish to miss an active vaccine we will design the study to have 
85% power with a one sided type I error rate of 0.1. We will also not adjust for the multiple comparisons 
([ADDRESS_42404] acebo).  
  
With [ADDRESS_42405] 85% power to detect a true difference in the primary 
immunogenicity endpoint of 0.[ADDRESS_42406] with significance level of 
0.1(R version 3.4.1).  
 
Table 1. Probability of observing at least [ADDRESS_42407] one  participant with  
SAE 
(Halting rule 1)  
N=10 N=40 
.001 0.01 0.04 
0.01 0.10  0.33 
0.02  0.18  0.55 
0.03  0.26  0.70 
0.04  0.34  0.80 
0.05  0.40  0.87 
0.06  0.46  0.92 
0.07  0.52  0.95 
0.08  0.57  0.96 
0.09  0.61  0.98 
0.1  0.65  0.99 
0.11 0.69 0.99 
0.12 .72 0.99 
0.13 0.75 0.99 
.14  0.78  0.99 
0.15 0.80 0.99 
 
 
 IND# [ZIP_CODE]  AGS -v PLUS  
Protocol, v 4.0 01 May  2020 AGS -v PLUS Mosquito Vax   
 
  
OCRPRO/DCR/NIAID/NIH  
CONFIDENTIAL  Page [ADDRESS_42408] 2 SAE’s for samples sizes of [ADDRESS_42409] 2AE’s  (halting rule 2)  
 N=10  N=40  
.01 <.001  .06 
.08 .19 .84 
.27 .80 >.[ADDRESS_42410] will be used. AEs will be tabulated by [CONTACT_2939].  
 
The fold increase in cellular and humoral responses to AGS -v PLUS f rom day 1 to days 43 and 50, and 
from day  43 to day 50  will be calculated for each participant . The mean fold increase s on each active 
group will be compare d to the mean fold increase s in the placebo group.  The geometric  mean antibody 
titers and geometric mean cytokine concentrations to AGS -v PLUS on days 1, 43 , and 50 will be 
calculated and compared between the different treatment groups.  
 
The fold increase in cellular responses to mosquito saliva  from day 1 to days 43 a nd 50, and from day 43 
to day 50 will be calculated for each participant. The mean fold increases on each active group will be 
compared to the mean fold increases in the placebo group.  The geometric mean cytokine concentrations 
to mosquito saliva  on days 1 , 43 and 50 will be calculated for each treatment group and compared to 
placebo . 
 
For the mosquito analysis, the following parameters will be compared on the active groups versus placebo  
for each mosquito  ( Aedes aegypti  and Aedes albopi[INVESTIGATOR_40643] ): 
-mean number  of days mosquitoes survive after feeding on vaccinated participants  
-mean number of eggs laid  
-mean number of mosquitoes emerging from the laid eggs  
 
For the visual assessment of the mosquito bite the following parameters will be calculated for each group  
and active groups will be compared to placebo at three different time points: day 43 ([ADDRESS_42411] feeding), 
day 45 and day 50:  
-mean number of visible bites  
-mean redness measured across the widest part (mm)  
-mean swelling measured using the ball point pe n method (mm2). Ball point pen measurement of 
induration uses the pen to slide on top of the skin so it halts at the edge of true induration (versus redness)  
 
From the biopsies taken on day 45, the following comparisons will be made:  
 IND# [ZIP_CODE]  AGS -v PLUS  
Protocol, v 4.0 01 May  2020 AGS -v PLUS Mosquito Vax   
 
  
OCRPRO/DCR/NIAID/NIH  
CONFIDENTIAL  Page 60 of 67 -gene expression: the level of expression of inflammatory cytokines at the bite site compared to normal 
skin (control) will be calculated for each participant for each mosquito bite. The mean will be calculated 
in each group and compared to placebo.  
 
The viability /infectivity  of Zika virus after culture with PBMCs and serum from vaccinated participants  will 
be assessed by [CONTACT_40747]. The higher the infectivity of the Zika virus the lower the MTT value will be for Vero 
cells.  The fold changes f rom day [ADDRESS_42412] immunization  and completed 
the Day 8 phone call  will be done by [CONTACT_40748] . Recruitment  activities will continue 
but vaccination of new participants will be halted until the DSMB  review  has been completed. Once the 
interim safety analysis is done on the initial enrolment , an additional set of  40 participant s will be enrolled 
and randomized using a permu ted block randomization with a block size of 10 .  
14.3.1 Interim  Analysis  
Data for all groups collected up to day 50 will undergo interim analysis for safety and immunogenicity, 
and an interim study report will be generated. Due to the importance of this data, these results may be 
shared with the greater scientific community via  meeting abstracts, professional presentations, and 
manuscript submissions to scientific journals. The data to be presented and the authorship will be 
approved by [CONTACT_30967] , vaccine developer , and sponsor before any official communication.  
 
15  Ethics/Protection of Human Participants  
  
15.1  Informed Consent Process  
Informed consent is a process where information is presented to enable persons to voluntarily decide 
whether or not to participate as a research participant. It is an ongoing conv ersation between the human 
research participant and the researchers, which begins before consent is given and continues until the 
end of the participant’s involvement in the research. Discussions about the research will provide essential 
information about the study and include: purpose, duration, experimental procedures, alternatives, risks, 
and benefits. Participants will be given the opportunity to ask questions and have them answered.   
  
The participants will sign the informed consent document before  undergoing any procedures. The 
participant may withdraw consent at any time throughout the course of the trial. A copy of the informed 
consent document will be given to the participants for th eir records. The researcher will document the 
signing of the consent form in the participant’s medical record. The rights and welfare of the participant 
will be protected by [CONTACT_40749].    
  
  
 IND# [ZIP_CODE]  AGS -v PLUS  
Protocol, v 4.0 01 May  2020 AGS -v PLUS Mosquito Vax   
 
  
OCRPRO/DCR/NIAID/NIH  
CONFIDENTIAL  Page [ADDRESS_42413] all documents and records 
required to be maintained by [CONTACT_093], inclu ding but not limited to medical records. Electronic 
records  will be kept in secure electronic systems. Clinical information will not be released without written 
permission of the participant, except as necessary for monitoring by [CONTACT_1744], the FDA, the NIAID, t he OHRP, 
or the sponsor’s designee.  
 
[ADDRESS_42414] Keepi[INVESTIGATOR_007]  
 
16.1  Data Capture and Management  
Study data will be collected and maintained in the study database  and collected directly from participants 
during study visits and telephone cal ls. Source documents include all recordings of observations or 
notations of clinical activities and all reports and records necessary to confirm the data abstracted for this 
study. Data entry into these systems will be performed by [CONTACT_4539]. The Investigator is 
responsible for assuring that the data collected are complete, accurate, and recorded in a timely manner.  
  
Data that may potentially unblind the vaccine assignment (e.g., vaccine preparation/accountability data, 
and vaccine allocation ) will be handled with special care to ensure that the integrity of the blind is 
maintained and the potential for bias is minimized. This can include making special provisions, such as 
segregating the data in question from view by [CONTACT_473], sponso r clinical team, or others as 
appropriate until the time of database lock and unblinding.  
16.[ADDRESS_42415] Retention  
The investigator is responsible for retaining all essential documents listed in the ICH GCP Guideline s and 
21 CFR 312.62 . Study records will be maintained at a minimum by [CONTACT_978] [INVESTIGATOR_8178] a period of 2 years following 
the date a marketing application is approved for the drug for the indication for which it is being investigated; 
or, if no application is to be filed or if the application is not approv ed for such indication, until [ADDRESS_42416]. All stored records 
will be kept confidential to the extent required by [CONTACT_1032], state, and local law.   
  
Should the investigator wish to assign the study records to another party and/or move them to another 
location, the investigator will provide written notification  of such intent to OCRPRO/NIAID with the name 
[CONTACT_40756]/or their new location. 
Destruction or relocation of research records will not proceed without written permission from 
NIAID/OCRPRO.  
IND#[ZIP_CODE]  AGS -v PLUS  
Protocol, v4.0  01 May  2020 AGS -v PLUS Mosquito Vax   
  
OCRPRO/DCR/NIAID/NIH  
CONFIDENTIAL  Page 62 of 67 SCIENTIFIC REFERENCES   
  
1. World Malaria Report 2015.  World Health Organization;2015.  
2. Bhattarai A, Ali AS, Kachur  SP, et al. Impact of artemisinin -based combination therapy and insecticide -
treated nets on malaria burden in Zanzibar. PLoS medicine. 2007;4(11):e309.  
3. Najera JA, Gonzalez -Silva M, Alonso PL. Some lessons for the future from the Global Malaria Eradication  
Programme (1955 -1969). PLoS medicine.  
2011;8(1):e1000412.  
4. Rts SCTP. Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a 
phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLoS medicine.  
2014;11(7):e1001685.  
5. Greenwood B, Targett G. Do we still need a malaria vaccine? Parasite immunology. 2009;31(9):582 -586.  
6. Ribeiro JM. Role of saliva in blood -feeding by [CONTACT_40750]. Annual review of entomology. 1987;32:463 -478.  
7. Wasserman HA, S ingh S, Champagne DE. Saliva of the Yellow Fever mosquito, Aedes aegypti, modulates 
murine lymphocyte function. Parasite immunology. 2004;26(6 -7):[ADDRESS_42417] of Aedes aegypti. The American journal of tropi[INVESTIGATOR_40667]. 1994;51(5):690 -
696.  
9. Silvestre R, Cordeiro -Da-Silva A, Santarem N, Vergnes B, Sereno D, Ouaissi  A. SIR2 -deficient Leishmania 
infantum induces a defined IFNgamma/IL -10 pattern that correlates with protection. Journal of immunology. 
2007;179(5):3161 -3170.  
10. Peng Z, Yang M, Simons FE. Immunologic mechanisms in mosquito allergy: correlation of skin react ions 
with specific IgE and IgG antibodies and lymphocyte proliferation response to mosquito antigens. Annals 
of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & 
Immunology. 1996;77(3):238 -244.  
11. Peng Z, Simon s FE. Mosquito allergy: immune mechanisms and recombinant salivary allergens. 
International archives of allergy and immunology. 2004;133(2):[ADDRESS_42418] infection with malaria parasites. Infection and immunity. 2007;75(5):[ADDRESS_42419] JK. Acquired immunity to malaria. Clin Microbiol Rev. 2009; 22(1): 13 -36. 
14. Sidjanski S, Vanderberg JP. Delayed migration of Plasmod ium sporozoites from the mosquito bite site to 
the blood. The American journal of tropi[INVESTIGATOR_40667]. 1997;57(4):426 -429.  
15. Ponnudurai T, Lensen AH, van Gemert GJ, Bolmer MG, Meuwissen JH. Feeding behaviour and sporozoite 
ejection by [CONTACT_40751]. Transactions of the Royal Society of Tropi[INVESTIGATOR_40668]. 1991;85(2):[ADDRESS_42420] cell interactions during sporozoite invasion. 
Bulletin of the World Health Organization.  
1990; [ADDRESS_42421]:74 -79.  
IND#[ZIP_CODE]  AGS -v PLUS  
Protocol, v4.0  01 May  2020 AGS -v PLUS Mosquito Vax   
  
OCRPRO/DCR/NIAID/NIH  
CONFIDENTIAL  Page 63 of 67 17. Vanderberg JP, Chew S, Stewart MJ. Plasmodium sporozoite interactions with macrophages in vitro: a 
videomicroscopic analysis. The Journal of protozoology. 1990;37(6):528 -536.  
18. Krettli AU, Dantas LA. Which routes do Plasmodium sporozoites u se for successful infections of 
vertebrates? Infection and immunity.  
2000;68(5):[ADDRESS_42422] immune response to 
mosquito -transmitted chikungunya virus differs from that elicited by [CONTACT_40752]. PloS one. 
2010;5(8):e12137.  
20. Schneider BS, Higgs S. The enhancement of arbovirus transmission and disease by [CONTACT_40753]. Transactions of the Royal Society of Tropi[INVESTIGATOR_40669]. 2008;102(5):400 -408.  
21. Brennan JD, Kent M, Dhar R, Fujioka H, Kumar N. Anopheles gambiae salivary gland proteins as putative 
targets for bl ocking transmission of malaria parasites. Proceedings of the National Academy of Sciences 
of the [LOCATION_002] of America. 2000;97(25):[ZIP_CODE] -[ZIP_CODE].  
22. Suneja A, Gulia M, Gakhar SK. Blocking of malaria parasite development in mosquito and fecundity 
reduction by [CONTACT_40754] (Diptera: Culicidae). Archives of insect biochemistry 
and physiology. 2003;52(2):[ADDRESS_42423] of anti -mosquito hemolymph antibodies on fecundity and on the 
infectivity of malarial parasite Plasmodium vivax to Anopheles stephensi (Diptera:Insecta). Japanese 
journal of infectious diseases. 2002;55(3):[ADDRESS_42424] multi ple influenza serotypes. European journal of immunology. 2007;37(9):2441 -2449.  
25. Vaughan JA, Scheller LF, Wirtz RA, Azad AF. Infectivity of Plasmodium berghei sporozoites delivered by 
[CONTACT_40755]: implications for sporozoite  vaccine trials. Infection and 
immunity.  
1999;67(8):[ADDRESS_42425] a defined anti -Leishmania vaccine targeting vector 
antigens: characterization of a protective salivary protein. The Journal of experimenta l medicine.  
2001;194(3):331 -342.  
27. Belkaid  Y, Kamhawi S, Modi G, et al. Development of a natural model of cutaneous leishmaniasis: powerful 
effects of vector saliva and saliva pre -exposure on the long -term outcome of Leishmania major infection in  
the mouse ear dermis. The Journal of experimental m edicine.  
1998;188(10):[ADDRESS_42426], Shaffer D, et al. Phase 1 trial of malaria transmission blocking vaccine candidates P fs25 
and Pvs25 formulated with M ontanide ISA 51. PloS one. 2008;3(7):e2636.  
29. Petrovsky N. Comparative safety of vaccine adjuvants: a summary of current evidence and future needs. 
Drug. Saf.  2015, 38(11): 1059 -1074.  
30. National Institutes of Health: Giving a subcutaneous injection 2015; 
http://www.cc.nih.gov/ccc/patient_education/pepubs/subq.pdf, 2016.  
IND# [ZIP_CODE]  AGS -v PLUS  
Protocol, v4.0  01 May 2020  AGS -v PLUS Mosquito Vax   
 
  
OCRPRO/DCR/NIAID/NIH  
CONFIDENTIAL  Page 64 of 67 Appendix A: Schedule of Procedures/Evaluations    
Study Phase >  Screen  Injec
tion 
1 Follow
-up 
call Injecti
on 2 Follow
-up 
call Feedin
g Follow
-up Follow -
up Follow
-up Follow
-up 
call 
Study Day >  DAY S 
-60 to 
0 D1 D8 D22 D29 D43 D45 D50 D181 D366  
Outpatient Visit  X X  X  X X X   
Comprehension quiz  X          
Written Consent  X          
Medical/Medication History  X X X X X X X X X X 
Physician Assessment and PE (targeted and as 
needed after screening)  X X  X  X X X   
Review of inclusion/exclusion  criteria and 
review of consent  X X  
X  
   
  
Vital signs  (temperature, heart rate, blood 
pressure)  X X  X  X  X   
Vital signs , Vaccine injection site and AE 
assessment pre -vaccination and  30-[ADDRESS_42427]  (serum/urine)‡  X X  X  X     
Vaccine administration   X  X       
Randomization   X         
Mosquito Feeding       X     
Mosquito Bite Assessment       X X X   
Safety Labs: hemoglobin, white blood cells, 
platelets, serum creatinine, serum alanine 
aminotransferase , random glucose  X X  X  X  X   
Screening Labs: HIV, hepatitis B and C  X          
Serum  and Whole Blood Collection    X    X  X   
Skin Biopsy        X    
Skin Biopsy inspection         X   
 † 
Vital Signs: participants must be sitting for a minimum of 5 minutes before  these procedures being 
performed; vital signs include blood pressure, heart rate, temperature . Weight  and height will be taken at 
the screening visit only.    
‡ 
Serum pregnancy testing at the screening and  urine pregnancy testing for  all other visits. On Days 1, 22, 
43, study vaccination or mosquito feeding will not be initiated until negative results are available. Females 
of childbearing potential only.  
  
IND# [ZIP_CODE]  AGS -v PLUS  
Protocol, v4.0  01 May 2020  AGS -v PLUS Mosquito Vax   
 
  
OCRPRO/DCR/NIAID/NIH  
CONFIDENTIAL  Page 65 of 67 Appendix B: Blood Volumes for Specimen Collection  
  
  Study 
Schedule/Procedures  Volume  Screening  Day 1 
prevaccination  Day 22  
prevaccination  Day 4 3 
(pre-
mosquito 
feeding)  Follow -up Day 
50 
Serum creatinine, serum 
alanine aminotransferase, 
hepatitis BsAg, hepatitis C 
Ab & b-hCG, Pregnancy , 
if needed  8.5 mL 
per blood 
draw  8.5 mL x x x x 
HIV 3.5 mL  3.5 mL  X X X X 
Complete blood count  4 mL per 
blood 
draw  4 mL 4 mL 4 mL 4 mL 4 mL 
Serum creatinine, serum 
alanine aminotransferase  5 mL per 
blood 
draw  x 5 mL 5 mL 5 mL 5 mL 
Serum for Immunology 
studies  4mL x 4mL x 4ml 
 4mL 
Whole blood for 
Immunology studies  50 mL x 50 mL x 50 ml  50 mL 
Daily Volume (mL)   16 mL 63 mL 9 mL  63 mL 63 mL 
Cumulative Volume    79 mL  88 mL  151 mL 214 mL 
IND# [ZIP_CODE]  AGS -v PLUS  
Protocol, v4.0  01 May 2020  AGS -v PLUS Mosquito Vax   
 
  
OCRPRO/DCR/NIAID/NIH  
CONFIDENTIAL  Page 66 of 67 Appendix C: Toxicity Tables   
 
Vital Signs  
Vital Signs  Mild (Grade 1)  Moderate (Grade 
2) Severe (Grade 3)  Potentially Life Threatening 
(Grade 4)  
Fever  ( C) * 
          38.0-38.4 
100.4 -101.2 ( F) 38.5-38.9 
101.3 -102.1( F) 39.0-40.0 
102.2 – 104.0 (F) >40.0 
>104 .0(F) 
Hypertension (systolic) 
mm Hg **  141-150 151-160 >160  ER visit or hospi[INVESTIGATOR_40670] (diastolic) 
mm Hg  91-95 96-100 >100  ER visit or hospi[INVESTIGATOR_40671] (systolic) mm 
Hg 85-89 80-84 <80 ER visit or hospi[INVESTIGATOR_40672] – beats per 
minute  50-54 
or 45 -50 if 
baseline <60  45-49 
or 40 -44 if baseline 
<60 <45 
or <40 if baseline 
<60 ER visit or hospi[INVESTIGATOR_40673] – beats per 
minute  101-115 116-130 >130  
or ventricular 
dysrhythmia  ER visit or hospi[INVESTIGATOR_40674]  
*  Oral temperature; no recent hot or cold beverages or smoking  
**  Assuming seated  position, [ADDRESS_42428] conditions, not sleepi[INVESTIGATOR_40675], measurements on the same arm and several concordant 
results  
Hematology  Mild  
(Grade 1)  Moderate  
(Grade 2)  Severe  
(Grade 3)  Potentially Life 
Threatening (Grade 4)  
WBC Decrease d –cell/mm3 2,500 – 3,500  1,500 – 2,499  1,000 – 1,499  <1,000  
WBC Increase d –cell/mm3 11,001 – 15,000  15,001 – 
20,000  20,001 – 25,000  >25,000  
Hgb g/dL (Female)  11.0 – 11.5 9.5 – 10.9 8.0 – 9.4 <8.0 
Hgb g/dL (Male)  12.0 – 12.5 10.0 – 11.9 8.5 – 9.9 <8.5 
Platelets Decrease d –cell/mm3 120,000 – 
130,000  100,000 – 
119,999  25,000 – 99,000  < 25,000  
     
Chemistry  Mild  
(Grade 1)  Moderate  
(Grade 2)  Severe  
(Grade 3)  Potentially Life 
Threatening (Grade 4)  
ALT Increase d IU/L  46 – 105 106 – 175 176 - 450 >450  
Creatinine mg/dL (Increase d) (Female)  >ULN – 1.7 1.8 – 2.0 2.1 – 2.5 >2.5 or requires dialysis  
Creatinine mg/dL (Increase d) (Male)  >ULN – 1.7 1.8 – 2.0 2.1 – 2.5 >2.5 or requires dialysis  
Glucose -hypoglycemia mg/dL  65-67 55-64 45 - 54 <45 
Glucose -hyperglycemia random - mg/dL  140-159 160-200 >200  Insulin requirements or 
hyperosmolar coma  
IND# [ZIP_CODE]  AGS -v PLUS  
Protocol, v4.0  01 May 2020  AGS -v PLUS Mosquito Vax   
 
  
OCRPRO/DCR/NIAID/NIH  
CONFIDENTIAL  Page 67 of 67 Appendix D: UMB IRB reporting guidelines  
 
